Biotech Industry Financials, Performance and Ratios
-
Industry Score
33.4 /100
Rank 91 out of 131 Industries -
Advance/Decline
214/94
-
No. of Companies308
-
Avg. Market Cap3,370
-
Price to Earning Ratio4.90
-
Price to Earning Growth Ratio1.38
-
Price to Book Ratio15.69
-
Return on Equity9.88
-
Return on Capital Employed-
-
Return on Assets4.84
-
Dividend yield 1 year %0.22 %
-
Net Profit Growth Annual YoY %81.23 %
-
Net Profit Growth Qtr YoY %-663.02 %
-
Net Profit Growth Qtr QoQ %-4768.82 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,051.6
|
22.1
|
L
 -8.6%
H
22.0
24.4
|
L
 -16.1%
H
22.0
28.0
|
L
 -10.4%
H
22.0
28.0
|
L
 -6.5%
H
19.4
28.0
|
L
 32.7%
H
16.9
28.0
|
L
 77.5%
H
8.0
28.0
|
L
 -37.4%
H
7.9
35
|
L
H
7.9
37.6
|
| IQVIA |
|
39,290.0
|
238.7
|
L
 2.7%
H
230.5
238.8
|
L
 1.6%
H
227.2
238.8
|
L
 17.1%
H
197.6
251.4
|
L
 33.6%
H
161.8
251.4
|
L
 32.7%
H
154.5
251.4
|
L
 9.1%
H
134.6
261.7
|
L
 -4.1%
H
134.6
285.6
|
L
 211.8%
H
70.1
285.6
|
| Nuvation Bio Inc (Class A) |
|
2,317.4
|
6.6
|
L
 8.0%
H
6.2
6.6
|
L
 4.3%
H
6.0
6.6
|
L
 12.4%
H
5.3
6.8
|
L
 37.8%
H
4.1
6.8
|
L
 187.0%
H
2.2
9.8
|
L
 222.0%
H
1.0
9.8
|
L
 -21.8%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
3,644.3
|
28.6
|
L
 1.0%
H
28.0
29.1
|
L
 1.5%
H
27.0
29.4
|
L
 -5.4%
H
25.7
31.1
|
L
 12.9%
H
21.8
31.7
|
L
 215.9%
H
8.9
31.7
|
L
 55.2%
H
6.5
31.7
|
L
 5.0%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
271.4
|
4.8
|
L
 1.3%
H
4.6
4.9
|
L
 23.6%
H
3.7
4.9
|
L
 20.2%
H
3.4
4.9
|
L
 19.9%
H
3.4
5.5
|
L
 172%
H
1.6
5.5
|
L
 -18.5%
H
1.2
7.2
|
L
 -84.6%
H
1.2
40.2
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
2,116.3
|
6.9
|
L
 6.1%
H
6.4
7.0
|
L
 21.4%
H
5.6
7.0
|
L
 -2.4%
H
5.0
7.5
|
L
 32.3%
H
3.9
8.4
|
L
 63.1%
H
2.7
8.4
|
L
 17.7%
H
1.9
8.4
|
L
 -53.7%
H
1.9
22.6
|
L
H
1.9
71.9
|
| Absci Corp |
|
1,512.7
|
8.9
|
L
 7.6%
H
8.5
9.0
|
L
 14.8%
H
7.4
9.0
|
L
 -19.6%
H
6.7
12
|
L
 51.4%
H
4.5
12.1
|
L
 214.4%
H
2.2
12.1
|
L
 388.0%
H
1.1
12.1
|
L
 -66.7%
H
1.1
28.3
|
L
H
1.1
31.5
|
| Adma Biologics Inc |
|
2,217.4
|
9.9
|
L
 -1.6%
H
9.8
10.2
|
L
 17.0%
H
8.6
10.4
|
L
 8.1%
H
8.2
10.4
|
L
 21.2%
H
7.5
10.4
|
L
 -40.1%
H
7.2
20.5
|
L
 139.1%
H
3.1
25.7
|
L
 526.6%
H
1.0
25.7
|
L
 58.4%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
3,965.4
|
24.9
|
L
 5.6%
H
24.3
25.0
|
L
 10.5%
H
21.8
25.0
|
L
 -69.1%
H
20.9
88.5
|
L
 -54.9%
H
20.9
91.2
|
L
 -48.9%
H
20.9
91.2
|
L
 -6.3%
H
9.1
91.2
|
L
 -82.3%
H
9.1
160
|
L
H
9.1
285
|
| Agenus Inc |
|
289.8
|
7.0
|
L
 -7.1%
H
6.9
7.6
|
L
 -7.2%
H
6.9
8.9
|
L
 114.2%
H
3.1
8.9
|
L
 82.2%
H
2.9
8.9
|
L
 45%
H
2.7
8.9
|
L
 -72.2%
H
1.4
196
|
L
 -93.7%
H
1.4
196
|
L
 -94.2%
H
1.4
196
|
| Change Agents Corp |
|
2.5
|
0.2
|
L
 -5%
H
0.2
0.2
|
L
H
0.2
0.2
|
L
 -34.5%
H
0.2
0.3
|
L
 -52.5%
H
0.2
0.4
|
L
 -91.4%
H
0.2
2.9
|
L
 -84.2%
H
0.2
11.7
|
L
 -98.1%
H
0.2
11.9
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
93.5
|
1.6
|
L
 -2.5%
H
1.5
1.6
|
L
 0.7%
H
1.5
1.6
|
L
 -27.2%
H
1.5
2.3
|
L
 -10.4%
H
1.5
2.5
|
L
 -70.5%
H
1.1
6.2
|
L
 -79.2%
H
1.1
7.9
|
L
 -84.2%
H
1.1
12.0
|
L
 -73.6%
H
1.1
16.7
|
| Alector Inc |
|
198.7
|
1.8
|
L
 -2.7%
H
1.7
2
|
L
 17.9%
H
1.5
2.0
|
L
 -2.7%
H
1.4
2.0
|
L
 -15.2%
H
1.4
2.4
|
L
 -17.2%
H
1.1
3.4
|
L
 -76.0%
H
0.9
8.9
|
L
 -93.6%
H
0.9
29.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
693.8
|
2.0
|
L
 2.0%
H
2.0
2.0
|
L
 6.9%
H
1.8
2.0
|
L
 -5.2%
H
1.6
2.2
|
L
 -11.8%
H
1.6
2.4
|
L
 93.3%
H
1.0
4.5
|
L
 -54.9%
H
0.9
5.8
|
L
 -91.4%
H
0.9
27.9
|
L
H
0.9
55
|
| Altimmune Inc |
|
599.0
|
3.1
|
L
 2.3%
H
3
3.1
|
L
 8.5%
H
2.9
3.1
|
L
 -1.0%
H
2.8
3.3
|
L
 -0.3%
H
2.6
3.4
|
L
 -10.7%
H
2.6
6.4
|
L
 2.3%
H
2.1
14.8
|
L
 -70.0%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,288.6
|
3.8
|
L
 0.3%
H
3.7
3.9
|
L
 -7.5%
H
3.7
4.1
|
L
 12.1%
H
3.0
4.1
|
L
 16.9%
H
2.9
4.6
|
L
 -55.0%
H
2.9
9.3
|
L
 -57.6%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
96.8
|
4.1
|
L
 -2.9%
H
4.0
4.3
|
L
 16.0%
H
3.5
4.4
|
L
 -13.6%
H
3.0
6.3
|
L
 -19.9%
H
3.0
6.3
|
L
 52.4%
H
2.1
11.9
|
L
 34.3%
H
0.4
12.9
|
L
 -80.1%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
290.4
|
2.1
|
L
 -0.5%
H
2.0
2.2
|
L
 8.3%
H
1.9
2.2
|
L
 -9.9%
H
1.9
2.4
|
L
 1.0%
H
1.4
2.4
|
L
 208.8%
H
0.6
2.7
|
L
 -58.3%
H
0.4
17.8
|
L
 -96.8%
H
0.4
81.2
|
L
H
0.4
117.5
|
| Amgen |
|
222,318.5
|
410.9
|
L
 1.5%
H
401.1
411.6
|
L
 6.7%
H
376.0
418.4
|
L
 11.7%
H
354.0
418.4
|
L
 23.9%
H
321.0
418.4
|
L
 42.6%
H
269.8
418.4
|
L
 57.6%
H
248.4
418.4
|
L
 78.6%
H
198.6
418.4
|
L
 138.4%
H
133.6
418.4
|
| AnaptysBio Inc |
|
1,676.1
|
56.6
|
L
 3.4%
H
55.1
57.4
|
L
 6.1%
H
51.9
57.4
|
L
 -13.4%
H
49.7
70.9
|
L
 -18.4%
H
49.7
70.9
|
L
 169.2%
H
17.1
73.3
|
L
 198.7%
H
12.2
73.3
|
L
 141.1%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,779.0
|
78.3
|
L
 -5.3%
H
74.3
78.6
|
L
 -1.3%
H
74.3
83.2
|
L
 -7.7%
H
74.3
85.9
|
L
 -4.4%
H
73.5
87.2
|
L
 -4.0%
H
70.2
99.5
|
L
 39.9%
H
48.2
99.5
|
L
 136.7%
H
22.3
99.5
|
L
 16.8%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
116.4
|
3.4
|
L
 -0.3%
H
3.4
3.5
|
L
H
3.4
3.6
|
L
 10.0%
H
3.0
3.9
|
L
 14%
H
2.3
3.9
|
L
 14.8%
H
2.3
5.5
|
L
 -3.1%
H
2.1
5.5
|
L
 -19.7%
H
2.1
6.5
|
L
 10.3%
H
0.6
8.1
|
| Aptevo Therapeutics Inc |
|
5.2
|
4.2
|
L
 2.7%
H
4.1
4.2
|
L
 1.7%
H
3.9
4.2
|
L
 -7.1%
H
3.7
4.9
|
L
 -15.9%
H
3.7
5.5
|
L
 -89.7%
H
3.7
48.8
|
L
 -100.0%
H
3.7
305676.8
|
L
 -100.0%
H
3.7
12940587.7
|
L
 -100.0%
H
3.7
52102512
|
| AquaBounty Tech Inc |
|
6.0
|
1.2
|
L
 9.4%
H
1.1
1.5
|
L
 28.6%
H
0.9
1.5
|
L
 24.5%
H
0.9
1.5
|
L
 24.5%
H
0.9
1.5
|
L
 56%
H
0.7
3.0
|
L
 -79.5%
H
0.5
6.1
|
L
 -98.8%
H
0.5
100.2
|
L
H
0.5
610
|
| Arvinas Inc |
|
572.1
|
8.8
|
L
 0.8%
H
8.6
9.0
|
L
 9.0%
H
7.9
9.7
|
L
 2.2%
H
7.9
9.7
|
L
 -13.5%
H
7.0
10.4
|
L
 39.1%
H
6.3
14.5
|
L
 -64.0%
H
5.9
53.1
|
L
 -90.8%
H
5.9
98.7
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
12,381.0
|
87.7
|
L
 2.1%
H
86.5
88.7
|
L
 3.5%
H
81.6
90.8
|
L
 2.2%
H
69.9
95.5
|
L
 20.6%
H
69.3
95.5
|
L
 433.8%
H
15.8
95.5
|
L
 218.8%
H
9.6
95.5
|
L
 35.3%
H
9.6
95.5
|
L
 1385.6%
H
1.2
95.5
|
| LeonaBio Inc |
|
72.1
|
7.7
|
L
 -1.7%
H
7.5
8.4
|
L
 8.8%
H
7.1
8.4
|
L
 -11.4%
H
6.7
10.1
|
L
 -23.5%
H
6.7
11.4
|
L
 95.9%
H
3.5
14.2
|
L
 -74.3%
H
2.2
43.0
|
L
 -92.3%
H
2.2
166.5
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
2,108.9
|
15.9
|
L
 -1.7%
H
15.6
16.6
|
L
 6.5%
H
14.5
16.6
|
L
 -2.3%
H
14.4
16.7
|
L
 4.1%
H
14.4
19.3
|
L
 39.4%
H
10.3
19.3
|
L
 63.2%
H
4.7
19.3
|
L
 9.9%
H
4.1
34.0
|
L
 331.9%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
826.5
|
8.0
|
L
 3.5%
H
7.7
8
|
L
 14.0%
H
6.8
8
|
L
 10.2%
H
6.6
8
|
L
 -4.9%
H
6.0
8.5
|
L
 17.5%
H
4.7
9.5
|
L
 -32.2%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
605.6
|
31.0
|
L
 2.5%
H
30.5
31.8
|
L
 10.5%
H
27.3
31.8
|
L
 -12.7%
H
27.2
36.3
|
L
 6.8%
H
26.7
39.5
|
L
 38.9%
H
14.4
39.5
|
L
 68.7%
H
1.4
61.1
|
L
 -66.6%
H
1.4
93.2
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,336.5
|
22.0
|
L
 -1.3%
H
21.7
23
|
L
 11.2%
H
18.6
23
|
L
 -2.5%
H
18.5
23.3
|
L
 -14.9%
H
14.3
26.8
|
L
 193.2%
H
6.7
28
|
L
 -95.9%
H
6.6
1134.5
|
L
 -95.3%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
309.5
|
3.3
|
L
 1.8%
H
3.3
3.4
|
L
 21.5%
H
2.7
3.4
|
L
 23.7%
H
2.3
3.4
|
L
 3.7%
H
2.3
3.4
|
L
 -69.9%
H
2.3
11.7
|
L
 -58.4%
H
2.3
14.4
|
L
 -82.7%
H
2.3
23.7
|
L
 5.4%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
10,947.6
|
212.7
|
L
 1.2%
H
208.6
214.4
|
L
 -2.4%
H
206.9
218.1
|
L
 -13.4%
H
206.9
249.6
|
L
 -2.1%
H
206.9
260.2
|
L
 103%
H
102.7
260.2
|
L
 193.3%
H
55.0
260.2
|
L
 315.8%
H
19.4
260.2
|
L
 2662.9%
H
1.9
260.2
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.9
|
L
 -3.4%
H
0.9
0.9
|
L
 -1.2%
H
0.8
0.9
|
L
 -10.5%
H
0.8
1.0
|
L
 -15.8%
H
0.8
1.3
|
L
 -57.7%
H
0.5
2.4
|
L
 -44.1%
H
0.5
2.6
|
L
 -89.5%
H
0.5
9.8
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
12.3
|
7
|
L
 -13.4%
H
7
8.0
|
L
 -10.9%
H
7
8.1
|
L
 -50.7%
H
7
15
|
L
 12%
H
3.0
29.3
|
L
 -82.3%
H
3.0
49.6
|
L
 -96.5%
H
3.0
208.3
|
L
 -99.5%
H
3.0
1504
|
L
 -99.9%
H
3.0
17759.8
|
| Argen X SE (ADR) |
|
54,117.8
|
865.0
|
L
 -1.2%
H
862.6
894.0
|
L
 1.3%
H
826.4
894.0
|
L
 -5.5%
H
826.4
935.9
|
L
 10.6%
H
775.6
953.6
|
L
 30.7%
H
631.5
953.6
|
L
 77.3%
H
327.7
953.6
|
L
 176.3%
H
249.5
953.6
|
L
H
17.3
953.6
|
| BridgeBio Pharma Inc |
|
16,546.4
|
84.5
|
L
 2.0%
H
82.2
85.0
|
L
 5.5%
H
78.8
85.0
|
L
 7.9%
H
78.8
93.4
|
L
 25.4%
H
62.5
93.4
|
L
 81.4%
H
46.3
93.4
|
L
 161.9%
H
21.6
93.4
|
L
 56.2%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioAtla Inc |
|
5.7
|
3.5
|
L
 3.9%
H
3.3
3.7
|
L
 5.2%
H
3.2
3.7
|
L
 -3.6%
H
3.2
4.3
|
L
 -28.5%
H
3.1
4.9
|
L
 -80.4%
H
3.1
71.5
|
L
 -97.3%
H
3.1
201
|
L
 -99.8%
H
3.1
2186.5
|
L
H
3.1
3831.5
|
| BioCardia Inc |
|
14.6
|
1.0
|
L
 3.2%
H
0.9
1.0
|
L
 19.5%
H
0.8
1.0
|
L
 2.1%
H
0.8
1
|
L
 -11.7%
H
0.8
1.8
|
L
 -45.3%
H
0.8
2.3
|
L
 -92.4%
H
0.8
23.3
|
L
 -98.1%
H
0.8
59.4
|
L
 -99.5%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,396.9
|
9.4
|
L
 0.9%
H
9.2
9.7
|
L
 4.5%
H
8.8
9.7
|
L
 -15.6%
H
8.8
11.2
|
L
 8.8%
H
8.1
11.2
|
L
 13.0%
H
6
11.2
|
L
 33.6%
H
4.0
11.3
|
L
 -46.7%
H
4.0
20.0
|
L
 123.9%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
31.7
|
3.6
|
L
 5.5%
H
3.5
3.7
|
L
 5.8%
H
3.3
3.7
|
L
 -1.6%
H
3.3
4
|
L
 -13.1%
H
2.6
4.3
|
L
 -94.9%
H
2.6
79
|
L
 -100.0%
H
2.6
11275.5
|
L
 -100.0%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
83250
|
| Black Diamond Therapeutics Inc |
|
112.0
|
2.0
|
L
 1.6%
H
1.9
2.0
|
L
 15.4%
H
1.7
2.0
|
L
 2.6%
H
1.6
2.0
|
L
 -34.8%
H
1.6
4.0
|
L
 -18.8%
H
1.6
4.9
|
L
 -43.6%
H
1.2
7.7
|
L
 -80.2%
H
1.2
10.5
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,838.3
|
27.5
|
L
 0.8%
H
27.1
28.4
|
L
 7.7%
H
24.7
28.5
|
L
 -25.5%
H
24.7
37.8
|
L
 -15.0%
H
24.7
38.3
|
L
 56.0%
H
15.6
38.3
|
L
 4.7%
H
13.5
49.5
|
L
 -74.6%
H
13.5
116.9
|
L
H
13
138.5
|
| BioVie Inc |
|
7.5
|
1
|
L
 -25.9%
H
1.0
1.2
|
L
 -34.2%
H
0.8
2.1
|
L
 -54.1%
H
0.8
2.3
|
L
 -32.0%
H
0.8
2.3
|
L
 -40.1%
H
0.8
2.3
|
L
 -99.7%
H
0.8
582
|
L
 -99.9%
H
0.8
1438
|
L
 -99.9%
H
0.8
5625
|
| Biomarin pharma Inc - Registered Shares |
|
12,351.9
|
63.8
|
L
 3.8%
H
62.2
64.9
|
L
 6.3%
H
58.9
64.9
|
L
 6.8%
H
57.4
64.9
|
L
 18.0%
H
49.3
64.9
|
L
 11.3%
H
49.3
66.3
|
L
 -29.6%
H
49.3
99.6
|
L
 -18.3%
H
49.3
117.8
|
L
 -35.6%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
13.3
|
1.2
|
L
 5.5%
H
1.1
1.2
|
L
 8.4%
H
1.1
1.2
|
L
 2.7%
H
1
1.2
|
L
 -10.1%
H
1
1.4
|
L
 -60.1%
H
1
5.5
|
L
 -71.1%
H
0.1
11.6
|
L
 -98.2%
H
0.1
63.7
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
468.2
|
13.6
|
L
 3.8%
H
13.1
13.8
|
L
 16.4%
H
11.5
13.8
|
L
 1.1%
H
11.1
13.8
|
L
 11.0%
H
10
14.3
|
L
 15.5%
H
9.9
16.8
|
L
 606.2%
H
1.9
17.2
|
L
 -79.2%
H
1.9
81.3
|
L
 -96.9%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
8.7
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
 -2.7%
H
1.1
1.2
|
L
 -10.1%
H
1.1
1.3
|
L
 -10.8%
H
1.1
1.5
|
L
 -18.3%
H
1.1
3.4
|
L
 -99.3%
H
1.1
173.5
|
L
 -100.0%
H
1.1
3465.5
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
27.8
|
0.9
|
L
 8.4%
H
0.8
0.9
|
L
 11.1%
H
0.8
0.9
|
L
 12.5%
H
0.7
1.2
|
L
 -26.2%
H
0.7
1.5
|
L
 -77.7%
H
0.7
8.1
|
L
 -87.7%
H
0.2
8.1
|
L
 -96.6%
H
0.2
36.5
|
L
H
0.2
71.5
|
| BioNTech SE (ADR) |
|
23,530.3
|
93.7
|
L
 2.7%
H
91.6
94.3
|
L
 3.4%
H
88.2
94.4
|
L
 0.2%
H
88.2
94.6
|
L
 -0.5%
H
85.0
98.8
|
L
 -16.1%
H
79.5
124
|
L
 -8.0%
H
76.5
131.5
|
L
 -75.9%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
454.9
|
2.8
|
L
 1.1%
H
2.7
2.8
|
L
 4.1%
H
2.6
2.8
|
L
 -10.9%
H
2.6
3.2
|
L
 -28.1%
H
2.6
4.1
|
L
 105.2%
H
1.3
4.2
|
L
 -77.1%
H
1.0
26.4
|
L
 -60.9%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
775.9
|
10.6
|
L
 0.1%
H
10.5
10.7
|
L
 5.8%
H
9.5
10.8
|
L
 7.2%
H
9.2
10.8
|
L
 26.8%
H
7.5
11.4
|
L
 75.9%
H
4.4
11.4
|
L
 862.7%
H
0.7
14.6
|
L
 40.6%
H
0.7
14.8
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
10.9
|
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
 -31%
H
0.7
1.0
|
L
 -23.3%
H
0.7
1
|
L
 9.5%
H
0.5
1.2
|
L
 -74.8%
H
0.5
7.2
|
L
 -78.7%
H
0.5
8.4
|
L
 -98.8%
H
0.5
63
|
L
H
0.5
530.3
|
| Tvardi Therapeutics Inc |
|
23.4
|
1.9
|
L
 1.1%
H
1.9
1.9
|
L
 -11.0%
H
1.8
2.1
|
L
 -62.6%
H
1.8
5.1
|
L
 -55.3%
H
1.5
5.7
|
L
 -92.2%
H
1.5
43.7
|
L
 -98.2%
H
1.5
117.6
|
L
 -99.6%
H
1.5
681.5
|
L
 -99.1%
H
1.5
1067.3
|
| C4 Therapeutics Inc |
|
412.4
|
3.7
|
L
 2.5%
H
3.7
3.8
|
L
 7.2%
H
3.4
3.8
|
L
 -11.0%
H
3.4
4.4
|
L
 26.4%
H
3.0
5.2
|
L
 49.2%
H
1.7
5.2
|
L
 6.3%
H
1.1
11.9
|
L
 -90.1%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
227.9
|
2.4
|
L
 4.8%
H
2.3
2.4
|
L
 2.6%
H
2.2
2.4
|
L
H
2.2
2.6
|
L
 -16.9%
H
2.0
3.1
|
L
 60.7%
H
1.3
3.2
|
L
 129.5%
H
0.5
3.2
|
L
 -64.8%
H
0.5
7.5
|
L
 -64.0%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
96.7
|
1.1
|
L
 -4.4%
H
1.1
1.1
|
L
 21.4%
H
0.9
1.2
|
L
 0.9%
H
0.9
1.2
|
L
 -10.7%
H
0.9
1.8
|
L
 42.1%
H
0.6
3.8
|
L
 -37.2%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Celldex Therapeutics Inc |
|
3,275.5
|
41.7
|
L
 0.4%
H
41.3
42.9
|
L
 9.6%
H
37.1
42.9
|
L
 7.1%
H
33.4
42.9
|
L
 22.8%
H
28.4
42.9
|
L
 101.9%
H
19.7
42.9
|
L
 28.7%
H
14.4
53.2
|
L
 -12.4%
H
14.4
57.2
|
L
 -38.5%
H
1.5
75.3
|
| Co-Diagnostics Inc |
|
5.6
|
1.5
|
L
 7.0%
H
1.4
1.5
|
L
 5.6%
H
1.3
1.7
|
L
 -42.4%
H
1.3
2.8
|
L
 -39.9%
H
1.3
13.5
|
L
 -80.1%
H
1.3
46.5
|
L
 -96.3%
H
1.3
66.9
|
L
 -99.5%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
213.0
|
4.0
|
L
 2.5%
H
3.8
4.2
|
L
 -16.0%
H
3.8
5.4
|
L
 -42.6%
H
3.8
8.8
|
L
 -67.6%
H
3.8
16.9
|
L
 -63.8%
H
3.8
21.4
|
L
 -81.8%
H
2.3
27.6
|
L
 -59.0%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
7,243.1
|
42.4
|
L
 1.4%
H
41.7
42.9
|
L
 8.9%
H
37.4
43.4
|
L
 6.1%
H
37.0
43.4
|
L
 22.0%
H
30.9
43.4
|
L
 286.8%
H
10.7
43.7
|
L
 257.1%
H
3.7
43.7
|
L
 483.1%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Coya Therapeutics Inc |
|
112.8
|
4.8
|
L
 5.0%
H
4.7
4.8
|
L
 14.8%
H
4.1
4.8
|
L
 -10.3%
H
3.9
5.6
|
L
 17.0%
H
3.9
6.2
|
L
 -20.9%
H
3.7
7.8
|
L
 23.3%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Caribou Biosciences Inc |
|
163.6
|
1.7
|
L
 0.6%
H
1.6
1.7
|
L
 13.0%
H
1.4
1.7
|
L
 -15.0%
H
1.4
2.0
|
L
 -15.0%
H
1.4
2.5
|
L
 -4.6%
H
1.4
3.5
|
L
 -74.8%
H
0.7
8.3
|
L
 -92.6%
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
163.7
|
1.4
|
L
 4.4%
H
1.4
1.4
|
L
 11.8%
H
1.2
1.4
|
L
 42%
H
1.0
1.4
|
L
 7.6%
H
1.0
1.4
|
L
 43.4%
H
0.9
1.7
|
L
 37.9%
H
0.7
3.1
|
L
 -34.9%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
7.8
|
4.0
|
L
 -8.8%
H
4.0
4.4
|
L
 -19.9%
H
4.0
5.5
|
L
 -18.6%
H
4.0
5.6
|
L
 -64.2%
H
3.6
11.7
|
L
 -88.3%
H
3.6
39
|
L
 -98.4%
H
3.6
349.8
|
L
 -99.9%
H
3.6
3616
|
L
 -99.9%
H
3.6
7440
|
| CorMedix Inc |
|
583.7
|
7.4
|
L
 -0.9%
H
7.4
7.6
|
L
 -1.2%
H
7.4
7.7
|
L
 -15.7%
H
7.1
8.9
|
L
 -6.1%
H
7.1
9.1
|
L
 -28.0%
H
6.1
15.0
|
L
 68.3%
H
2.6
17.4
|
L
 23.8%
H
2.6
17.4
|
L
 4.1%
H
0.9
18.8
|
| CRISPR Therapeutics AG |
|
5,175.0
|
53.5
|
L
 3.6%
H
52.2
54.2
|
L
 11.5%
H
47.5
54.2
|
L
 -9.6%
H
45.9
60.5
|
L
 -2.4%
H
45.9
63.5
|
L
 -2.7%
H
44.1
78.5
|
L
 0.9%
H
30.0
91.1
|
L
 -60.9%
H
30.0
142.6
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
72.1
|
5.2
|
L
H
5
5.3
|
L
 -3.2%
H
5
5.8
|
L
 -14.5%
H
5
6.5
|
L
 -13.8%
H
5
7
|
L
 -19.0%
H
5
8.7
|
L
 -17.6%
H
3.6
12.0
|
L
 -50.8%
H
3.6
12.0
|
L
 160.8%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
113.9
|
27.1
|
L
 0.4%
H
26.9
27.6
|
L
 1.0%
H
26.0
28.5
|
L
 -23.3%
H
25.3
45.5
|
L
 -22.5%
H
18.2
45.5
|
L
 8.8%
H
5.0
45.5
|
L
 -74.7%
H
5.0
111.9
|
L
 -91.6%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
7.0
|
2.0
|
L
 4.3%
H
1.9
2.1
|
L
 -3.0%
H
1.9
2.2
|
L
 -37.1%
H
1.9
3.2
|
L
 -68.0%
H
1.9
6.3
|
L
 -82.5%
H
1.9
14.6
|
L
 153.2%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
14.1
|
1.9
|
L
 7.2%
H
1.8
2.0
|
L
 24.5%
H
1.5
2.0
|
L
 -2.0%
H
1.4
2.1
|
L
 9.0%
H
1.4
2.8
|
L
 -50.3%
H
1.4
4.1
|
L
 -61.1%
H
1.4
10.2
|
L
 -97.1%
H
1.4
71.2
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,827.2
|
13.5
|
L
 -0.1%
H
13.3
14.1
|
L
 19.3%
H
11.0
14.1
|
L
 -3.0%
H
10.6
14.6
|
L
 36.6%
H
9.2
15.4
|
L
 208.4%
H
4.0
15.4
|
L
 65.9%
H
2.3
15.4
|
L
 -59.8%
H
2.3
49.5
|
L
H
2.3
61.7
|
| DiaMedica Therapeutics Inc |
|
363.7
|
6.8
|
L
 -0.3%
H
6.7
6.9
|
L
 6.5%
H
6.3
6.9
|
L
 -15.2%
H
6.3
8.0
|
L
 6.8%
H
5.2
8.5
|
L
 44.5%
H
4.4
10.4
|
L
 118.4%
H
1.9
10.4
|
L
 98.5%
H
1.1
10.4
|
L
 87.5%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,969.0
|
24.8
|
L
 0.4%
H
24.2
25.7
|
L
 7.9%
H
22.6
25.7
|
L
 -7.0%
H
22.0
27.3
|
L
 26.6%
H
17.7
27.3
|
L
 77.9%
H
12.6
27.3
|
L
 -3.9%
H
10.6
33.3
|
L
 -52.3%
H
10.6
56.8
|
L
H
10.6
93.9
|
| Bright Minds Biosciences Inc |
|
778.4
|
79.3
|
L
 -1.8%
H
78
83
|
L
 8.3%
H
71.0
83
|
L
 13.5%
H
68.8
83
|
L
 -7.2%
H
56.5
92
|
L
 104.4%
H
37.5
123.8
|
L
 1802.4%
H
0.9
123.8
|
L
 225.8%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
875.5
|
14.0
|
L
 1.6%
H
13.7
14.2
|
L
 14.9%
H
11.7
14.2
|
L
 -8.4%
H
11.4
15.7
|
L
 -1.6%
H
9.9
17.0
|
L
 226.9%
H
4.2
17.3
|
L
 90.6%
H
1.9
17.3
|
L
 -8.6%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
206.7
|
7.5
|
L
 0.9%
H
7.4
7.8
|
L
 7.2%
H
6.9
7.8
|
L
 -19.3%
H
6.7
9.6
|
L
 -2.6%
H
6
9.6
|
L
 71%
H
3.5
9.6
|
L
 1313.2%
H
0.3
19.4
|
L
 -27.7%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
4,902.1
|
26.3
|
L
 1.4%
H
25.2
26.3
|
L
 4.3%
H
24.2
27.1
|
L
 10.2%
H
21.3
27.1
|
L
 49.1%
H
15.9
27.1
|
L
 135.2%
H
10.8
27.1
|
L
 164.4%
H
6.4
47.5
|
L
 38.2%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
442.3
|
2.9
|
L
 -0.7%
H
2.9
3.1
|
L
 11.6%
H
2.5
3.1
|
L
 -21.5%
H
2.5
3.7
|
L
 -7.4%
H
2.4
3.9
|
L
 30.3%
H
1.7
4.5
|
L
 -67.6%
H
0.9
11.7
|
L
 -94.8%
H
0.9
73.0
|
L
 -87.8%
H
0.9
100.0
|
| Eloxx Pharma |
|
60.4
|
17.6
|
L
 -0.8%
H
17.4
18.4
|
L
 0.8%
H
15.7
19.4
|
L
 43.4%
H
10.5
19.4
|
L
 331.7%
H
8.2
19.4
|
L
 331.7%
H
8.2
19.4
|
L
 170.7%
H
0
19.4
|
L
 -69.3%
H
0
75.6
|
L
 -87.8%
H
0
984
|
| Elicio Therapeutics Inc |
|
83.8
|
3.2
|
L
 1.6%
H
3.1
3.3
|
L
 13.9%
H
2.8
3.3
|
L
 -8.6%
H
2.7
3.6
|
L
 -67.8%
H
2.7
16
|
L
 -65.3%
H
2.7
16
|
L
 -68.1%
H
2.7
16
|
L
 -97.1%
H
2.7
141.8
|
L
H
2.7
263
|
| Enliven Therapeutics Inc |
|
4,430.0
|
60.5
|
L
 0.3%
H
59.7
61.8
|
L
 10.3%
H
52.7
62.3
|
L
 19.0%
H
49.5
62.3
|
L
 48.4%
H
33.5
62.3
|
L
 241.8%
H
14.8
62.3
|
L
 240.8%
H
9.8
62.3
|
L
 161.1%
H
3.9
62.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
804.1
|
14
|
L
H
13.6
14.5
|
L
 17.7%
H
11.4
14.5
|
L
 3.2%
H
11.4
14.5
|
L
 23.1%
H
9.3
14.5
|
L
 723.5%
H
1.5
14.5
|
L
 414.7%
H
1.1
14.5
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
35.0
|
2.1
|
L
 5.1%
H
1.9
2.1
|
L
 -0.5%
H
1.9
2.3
|
L
 -71.2%
H
1.8
7.6
|
L
 170.1%
H
0.4
7.6
|
L
 45.5%
H
0.4
7.6
|
L
 -19.7%
H
0.4
7.6
|
L
 -74.8%
H
0.4
14.0
|
L
 -96.8%
H
0.4
81.6
|
| Enochian Biosciences Inc |
|
-
|
2.4
|
L
 -0.4%
H
2.4
2.6
|
L
 24.2%
H
1.9
3.8
|
L
 -12.0%
H
1.9
3.8
|
L
 630.3%
H
0.2
5.0
|
L
 864%
H
0.1
5.0
|
L
 183.5%
H
0.1
5.0
|
L
 -58.2%
H
0.1
13.8
|
L
 129.5%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
8.0
|
0.5
|
L
H
0.5
0.6
|
L
 108%
H
0.3
1.0
|
L
 85.7%
H
0.2
1.0
|
L
 48.6%
H
0.2
1.0
|
L
 -76.2%
H
0.2
2.8
|
L
 -72.5%
H
0.1
9.9
|
L
 -99.9%
H
0.1
1680
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
133.4
|
2.1
|
L
 -0.5%
H
2.1
2.2
|
L
 -4.1%
H
2.1
2.3
|
L
 -33.0%
H
2.1
3.2
|
L
H
1.8
3.5
|
L
 322%
H
0.8
3.5
|
L
 174.0%
H
0.3
3.5
|
L
 -65.0%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Evogene Ltd |
|
7.3
|
0.6
|
L
 -11.8%
H
0.6
0.7
|
L
 27.7%
H
0.5
0.7
|
L
 46.3%
H
0.4
0.7
|
L
 -20%
H
0.4
0.8
|
L
 -50.4%
H
0.4
1.5
|
L
 -93.3%
H
0.4
10.4
|
L
 -97.8%
H
0.4
35.8
|
L
 -99.1%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,726.5
|
43.5
|
L
 -2.0%
H
42.5
44.2
|
L
 13.2%
H
36.9
45.9
|
L
 -6%
H
36.9
48.4
|
L
 23.2%
H
30.8
48.4
|
L
 243.2%
H
12.3
48.4
|
L
 595.2%
H
5.1
48.4
|
L
 139.3%
H
5.1
48.4
|
L
H
5.1
48.4
|
| Evaxion Biotech A/S (ADR) |
|
25.9
|
3.1
|
L
 3.3%
H
3.0
3.1
|
L
 9.9%
H
2.8
3.1
|
L
 -4.6%
H
2.8
3.4
|
L
 -28.6%
H
2.8
4.5
|
L
 9.5%
H
2.5
12.2
|
L
 -68.4%
H
0.8
13.6
|
L
 -94.8%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
326.4
|
2.8
|
L
 12.5%
H
2.5
2.9
|
L
 14.3%
H
2.4
2.9
|
L
 -4.4%
H
2.3
3.2
|
L
 17.2%
H
1.6
3.2
|
L
 204.4%
H
0.9
3.2
|
L
 -20.7%
H
0.7
8.8
|
L
 -97.1%
H
0.7
97.4
|
L
 8.1%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
1,573.4
|
76.8
|
L
 -0.1%
H
76.8
76.9
|
L
 0.3%
H
76.5
76.9
|
L
 273.1%
H
21.3
77.2
|
L
 219.7%
H
15.5
77.2
|
L
 654.3%
H
9.9
77.2
|
L
 256.2%
H
4.1
77.2
|
L
 -88.6%
H
4.1
786.8
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
562.0
|
10.8
|
L
 1.9%
H
10.5
10.8
|
L
 5.6%
H
9.7
10.8
|
L
 -17.4%
H
9.4
13.4
|
L
 6.0%
H
8.1
14
|
L
 90.9%
H
5.3
14
|
L
 -36.5%
H
2.2
36.3
|
L
 -60.3%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
402.3
|
11.6
|
L
 6.8%
H
11.0
11.7
|
L
 21%
H
9.5
11.7
|
L
 13.0%
H
9.4
11.7
|
L
 67.1%
H
6.8
11.7
|
L
 39.0%
H
5.7
11.7
|
L
 42.1%
H
4.0
11.9
|
L
 70.0%
H
3.8
11.9
|
L
 417.0%
H
1.6
15.0
|
| Foghorn Therapeutics Inc |
|
360.5
|
6.1
|
L
 9.0%
H
5.5
6.2
|
L
 34%
H
4.5
6.2
|
L
 -1.6%
H
4.4
6.3
|
L
 36.7%
H
3.5
6.6
|
L
 32.5%
H
3.3
7.0
|
L
 -34.4%
H
2.7
10.2
|
L
 -28.5%
H
2.7
24.3
|
L
H
2.7
28.3
|
| First Wave BioPharma Inc |
|
4.3
|
2.7
|
L
 -4.9%
H
2.7
2.9
|
L
 -5.5%
H
2.7
3.1
|
L
 -36.3%
H
2.6
4.5
|
L
 -19.9%
H
2.6
6.9
|
L
 661.1%
H
0.5
6.9
|
L
 -70.3%
H
0.4
22.2
|
L
 -100.0%
H
0.4
35991.6
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
347.9
|
3.5
|
L
 7.1%
H
3.2
3.6
|
L
 16.2%
H
2.7
3.6
|
L
 -23.5%
H
2.7
5.6
|
L
 64.3%
H
2.1
5.6
|
L
 -16.9%
H
2.0
7.1
|
L
 146.4%
H
0.7
7.1
|
L
 0.3%
H
0.7
7.1
|
L
 59.7%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
77.6
|
1.8
|
L
 2.3%
H
1.8
1.9
|
L
 8.3%
H
1.7
1.9
|
L
 1.7%
H
1.6
1.9
|
L
H
1.5
2.2
|
L
 23.0%
H
1.5
4.3
|
L
 -51.2%
H
0.9
5.3
|
L
 -77.3%
H
0.9
9.8
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
9.7
|
0.8
|
L
 2.5%
H
0.8
0.9
|
L
 -11.8%
H
0.8
1.0
|
L
 -15.5%
H
0.7
1.2
|
L
 5.1%
H
0.7
1.4
|
L
 -56.2%
H
0.7
3.7
|
L
 -80.8%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
949.5
|
1.5
|
L
 -5.7%
H
1.5
1.6
|
L
 14.7%
H
1.2
1.6
|
L
 -5.1%
H
1.2
1.6
|
L
 6.5%
H
1.1
1.6
|
L
 15.6%
H
1.0
2.0
|
L
 -50%
H
1.0
5.3
|
L
 18.4%
H
1.0
5.3
|
L
 -45.6%
H
0.8
7.0
|
| Gilead Sciences |
|
165,174.4
|
133.2
|
L
 1.8%
H
130.6
134.1
|
L
 2.3%
H
129.0
137.8
|
L
 -1.9%
H
127.6
140.6
|
L
 1.4%
H
121.4
140.6
|
L
 11.6%
H
108.5
157.3
|
L
 66.3%
H
62.1
157.3
|
L
 93.7%
H
57.2
157.3
|
L
 67.1%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
210.8
|
14.4
|
L
 0.8%
H
14.2
14.7
|
L
 6.4%
H
13.2
15.0
|
L
 -23.9%
H
12.5
21.7
|
L
 -37.2%
H
12.5
29.9
|
L
 17.9%
H
7.8
34.1
|
L
 41.9%
H
7.6
34.1
|
L
 -64.0%
H
6.8
48.5
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,354.8
|
15.9
|
L
 1.1%
H
15.7
16.1
|
L
 -3.9%
H
15.1
17.2
|
L
 -34%
H
14.9
25.2
|
L
 -18.1%
H
14.9
25.2
|
L
 262.6%
H
4.2
25.8
|
L
 131.1%
H
2.4
25.8
|
L
 -48.2%
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
4.0
|
0.8
|
L
 6.9%
H
0.7
0.8
|
L
 13.2%
H
0.7
0.8
|
L
 -33.6%
H
0.6
1.2
|
L
 -53.9%
H
0.6
4.4
|
L
 -95.5%
H
0.6
20
|
L
 -99.6%
H
0.6
276.8
|
L
 -100.0%
H
0.6
2812.5
|
L
 -100.0%
H
0.6
379518072.3
|
| GRI Bio Inc |
|
2.6
|
1.5
|
L
 -5.2%
H
1.4
1.6
|
L
 6.5%
H
1.4
1.6
|
L
 -17.0%
H
1.4
1.9
|
L
 -34.4%
H
1.4
2.4
|
L
 -95.8%
H
1.4
80.4
|
L
 -100.0%
H
1.4
159667.1
|
L
 -100.0%
H
1.4
13462627.3
|
L
H
1.4
13462627.3
|
| Graphite Bio Inc |
|
312.1
|
5.4
|
L
 2.7%
H
5.2
5.4
|
L
 1.1%
H
4.9
5.5
|
L
 -12.6%
H
4.7
6.2
|
L
 -46.7%
H
4.7
10.6
|
L
 -84.5%
H
4.7
50.4
|
L
 -95.8%
H
4.7
413
|
L
 -99.5%
H
4.7
1145.1
|
L
H
4.7
1666
|
| Galapagos NV (ADR) |
|
1,779.2
|
27
|
L
 3.3%
H
26.6
27.1
|
L
 -0.8%
H
25.7
27.1
|
L
 -12.4%
H
25.7
30.9
|
L
 -5.6%
H
25.7
30.9
|
L
 -17.1%
H
25.7
37.8
|
L
 -30.8%
H
22.4
42.5
|
L
 -55.1%
H
22.4
72.1
|
L
 -49.9%
H
22.4
274.0
|
| Genmab (ADR) |
|
19,485.4
|
31.3
|
L
 4.8%
H
30.9
31.8
|
L
 8.2%
H
28.1
31.8
|
L
 5.8%
H
27.9
31.8
|
L
 18.2%
H
23.6
31.8
|
L
 45.8%
H
21
35.4
|
L
 -16.8%
H
17.2
39.5
|
L
 -31.5%
H
17.2
49.1
|
L
 74.5%
H
12.1
49.1
|
| Halozyme Therapeutics Inc |
|
12,231.4
|
103.1
|
L
 20.2%
H
90
103.3
|
L
 24.9%
H
81.8
103.3
|
L
 28.3%
H
73.9
103.3
|
L
 60.8%
H
63.5
103.3
|
L
 63.9%
H
61.2
103.3
|
L
 138.1%
H
32.8
103.3
|
L
 154.6%
H
29.9
103.3
|
L
 922.0%
H
8.2
103.3
|
| HCW Biologics Inc |
|
5.4
|
3.4
|
L
H
3.3
3.6
|
L
 6.6%
H
3.1
4.2
|
L
 -23.0%
H
2.4
4.8
|
L
 73.1%
H
1.8
23.9
|
L
 -87.7%
H
1.5
44.1
|
L
 -100.0%
H
1.5
24192
|
L
 -100.0%
H
1.5
67680
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
22.0
|
1.9
|
L
 0.5%
H
1.8
1.9
|
L
 -3.1%
H
1.8
2.0
|
L
 -19.4%
H
1.8
2.5
|
L
 -38.1%
H
1.8
3.9
|
L
 52.0%
H
1.1
9.1
|
L
 -77.3%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
92.7
|
0.5
|
L
 -2%
H
0.5
0.5
|
L
 -2%
H
0.5
0.5
|
L
 8.9%
H
0.4
0.5
|
L
 -59.5%
H
0.4
1.1
|
L
 -62.9%
H
0.4
1.6
|
L
 -70.7%
H
0.4
3.9
|
L
 -95.8%
H
0.4
12.9
|
L
 -97.4%
H
0.4
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
22.1
|
3.5
|
L
 6.8%
H
3.2
3.7
|
L
 19.4%
H
2.7
3.7
|
L
 5.5%
H
2.7
3.7
|
L
 -29.3%
H
2.7
10.8
|
L
 -88.2%
H
2.1
31.9
|
L
 -96.1%
H
2.1
109.2
|
L
 -96.9%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
194.1
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 10.8%
H
0.7
0.7
|
L
 -1.4%
H
0.6
0.7
|
L
 -32.1%
H
0.6
1.5
|
L
 -71.0%
H
0.6
2.6
|
L
 -76.8%
H
0.6
10.0
|
L
 -92.8%
H
0.6
17.5
|
L
H
0.6
17.5
|
| Immucell Corp |
|
99.5
|
11
|
L
 -0.2%
H
10.8
11.0
|
L
 -1.9%
H
10.5
11.4
|
L
 3.5%
H
10.5
12.1
|
L
 36.7%
H
8.1
12.1
|
L
 65.2%
H
4.5
12.1
|
L
 116.5%
H
3.3
12.1
|
L
 12.6%
H
3.3
12.1
|
L
 40.5%
H
3.3
13.2
|
| InflaRx N.V. |
|
271.0
|
1.8
|
L
 7.0%
H
1.8
1.9
|
L
 8.2%
H
1.7
1.9
|
L
 -14.8%
H
1.6
2.3
|
L
 -28.7%
H
1.5
2.9
|
L
 130%
H
0.8
3.0
|
L
 -48.5%
H
0.7
4.3
|
L
 -29.8%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
64.6
|
5.7
|
L
 1.1%
H
5.3
5.8
|
L
 2.7%
H
5.3
5.8
|
L
 -3.9%
H
5.3
6.3
|
L
 7.6%
H
5.1
6.3
|
L
 -61.2%
H
3.9
15.3
|
L
 -89.1%
H
3.9
62.5
|
L
 -95.4%
H
3.9
210
|
L
H
3.9
451.3
|
| Immunome Inc |
|
2,834.7
|
25.0
|
L
 -3.1%
H
24.8
26.3
|
L
 10.0%
H
22.1
26.4
|
L
 4.3%
H
21.6
26.4
|
L
 11.5%
H
17.8
26.4
|
L
 158.3%
H
8.7
27.7
|
L
 248.1%
H
5.2
31.0
|
L
 56.9%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
6.8
|
1.6
|
L
 1.9%
H
1.6
1.6
|
L
 1.3%
H
1.6
1.7
|
L
 -21.8%
H
1.5
2.2
|
L
 -40.8%
H
1.5
2.8
|
L
 -77.6%
H
1.5
7.2
|
L
 -91.5%
H
1.5
54.8
|
L
 -99.3%
H
1.5
265.5
|
L
 -100.0%
H
1.5
4410
|
| Immunovant Inc |
|
8,251.8
|
40.0
|
L
 0.5%
H
39.0
40.3
|
L
 3.4%
H
36.8
40.3
|
L
 -0.9%
H
36.8
41.2
|
L
 38.0%
H
25.8
41.2
|
L
 158.4%
H
14.3
41.2
|
L
 83.5%
H
12.7
45.6
|
L
 415.5%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
9.4
|
1.0
|
L
 1.0%
H
1.0
1.0
|
L
 -5.8%
H
0.9
1.1
|
L
 -29.0%
H
0.9
1.5
|
L
 -38.0%
H
0.9
1.9
|
L
 -57.6%
H
0.9
2.7
|
L
 -16.2%
H
0.1
4.2
|
L
 -89.9%
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,200.5
|
88.7
|
L
 3.4%
H
80.4
89.3
|
L
 8.1%
H
80.4
89.3
|
L
 -8.7%
H
77.5
106.4
|
L
 -34.0%
H
77.5
151.0
|
L
 321.0%
H
20.6
155.3
|
L
 421.2%
H
10.8
155.3
|
L
 224.0%
H
7.7
155.3
|
L
H
7.7
155.3
|
| MiNK Therapeutics Inc |
|
54.6
|
11.0
|
L
 -0.5%
H
10.9
11.6
|
L
 4.3%
H
10.5
12.0
|
L
 3.8%
H
10.2
12.0
|
L
 -0.8%
H
9.5
13.4
|
L
 -9.2%
H
8.5
18.2
|
L
 -40.8%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
57.7
|
2.1
|
L
 8.9%
H
1.9
2.1
|
L
 18.9%
H
1.7
2.1
|
L
 20.9%
H
1.6
2.2
|
L
 45.5%
H
1.2
2.2
|
L
 -18.8%
H
1.1
2.6
|
L
 -73.5%
H
1.1
14.7
|
L
 -86.9%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
2,871.8
|
6.3
|
L
 2.1%
H
5.9
6.9
|
L
 55.8%
H
4.0
6.9
|
L
 48.1%
H
3.8
6.9
|
L
 75.1%
H
3.3
6.9
|
L
 200.5%
H
1.8
6.9
|
L
 -11.2%
H
1.6
18.3
|
L
 -73.1%
H
1.6
28.0
|
L
 -31.2%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
61.6
|
1.3
|
L
 2.3%
H
1.3
1.3
|
L
 1.6%
H
1.3
1.5
|
L
 -9.0%
H
1.1
1.5
|
L
 3.2%
H
1.1
2.0
|
L
 -34.5%
H
1.0
3.3
|
L
 -39.9%
H
0.3
3.3
|
L
 -81.9%
H
0.3
8.7
|
L
 6450%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
360.7
|
2
|
L
 5.3%
H
1.9
2.0
|
L
 -1.0%
H
1.9
2.1
|
L
 -17.7%
H
1.9
2.5
|
L
 -12.7%
H
1.9
2.6
|
L
 292.2%
H
0.4
3.0
|
L
 -31.0%
H
0.3
5.5
|
L
 -93.4%
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,973.1
|
77.4
|
L
H
76.8
78.8
|
L
 0.6%
H
75.2
81.0
|
L
 -3.3%
H
71.6
81.6
|
L
 13.5%
H
63.8
82.5
|
L
 33.5%
H
40
99.5
|
L
 58.2%
H
25.6
99.5
|
L
 94.1%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
218.0
|
0.7
|
L
 12.1%
H
0.7
0.8
|
L
 37.0%
H
0.5
0.8
|
L
 -10.8%
H
0.5
0.9
|
L
 -50.7%
H
0.5
1.6
|
L
 -7.5%
H
0.5
3.1
|
L
 -51.0%
H
0.4
5.2
|
L
 -96.5%
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,729.4
|
34
|
L
 -1.5%
H
33.2
34.6
|
L
 0.6%
H
32.0
34.6
|
L
 0.7%
H
30.3
36.3
|
L
 14.9%
H
27.6
36.3
|
L
 6.4%
H
27.6
40.7
|
L
 -45.9%
H
23.2
77.0
|
L
 6.3%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
57.5
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 -9.3%
H
0.4
0.5
|
L
 -13.3%
H
0.4
0.6
|
L
 -78.2%
H
0.3
3.5
|
L
 -80.9%
H
0.3
3.5
|
L
 -89.4%
H
0.3
5
|
L
 -87.0%
H
0.3
8.0
|
| Inventiva (ADR) |
|
1,133.9
|
4.8
|
L
 3%
H
4.8
4.9
|
L
 7.1%
H
4.2
4.9
|
L
 9.3%
H
4.2
4.9
|
L
 -10.6%
H
3.4
6.1
|
L
 34.1%
H
3.4
8.0
|
L
 24.0%
H
1.5
8.0
|
L
 -57.2%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
966.6
|
15.9
|
L
 -1.6%
H
15.7
16.2
|
L
 4.5%
H
14.9
16.4
|
L
 -4.9%
H
14.6
16.9
|
L
 11.8%
H
13.0
16.9
|
L
 -30.6%
H
12.1
35.3
|
L
 33.5%
H
5.7
71.7
|
L
 -48.0%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
23.6
|
0.7
|
L
 9.2%
H
0.7
0.8
|
L
 12.7%
H
0.6
0.8
|
L
 36.5%
H
0.5
1.0
|
L
 -23.7%
H
0.3
1.0
|
L
 -71.0%
H
0.3
3.1
|
L
 -51.7%
H
0.3
31.0
|
L
H
0.3
31.0
|
L
H
0.3
31.0
|
| Kamada Ltd |
|
419.4
|
7.3
|
L
 1.8%
H
7.2
7.3
|
L
 1.8%
H
7.1
7.4
|
L
 -0.1%
H
6.9
7.4
|
L
 -15.0%
H
6.9
8.7
|
L
 2.1%
H
6.5
9.4
|
L
 39.3%
H
4.1
9.4
|
L
 29.1%
H
3.7
9.4
|
L
 75.2%
H
3.7
13.3
|
| Kodiak Sciences Inc |
|
2,839.2
|
45.4
|
L
 -0.1%
H
45.1
46.9
|
L
 9.1%
H
39.4
46.9
|
L
 11.7%
H
37.1
46.9
|
L
 10.6%
H
29.2
46.9
|
L
 474.3%
H
7.8
47.8
|
L
 1412.3%
H
1.4
47.8
|
L
 -45.8%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
9,662.5
|
326.5
|
L
 1.2%
H
320.3
329
|
L
 -4.3%
H
297.0
332.3
|
L
 -13.0%
H
297.0
382.1
|
L
 6.8%
H
285.1
382.5
|
L
 135.4%
H
136.7
382.5
|
L
 181.7%
H
94.0
382.5
|
L
 445.0%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
135.6
|
2.1
|
L
 0.5%
H
2.1
2.2
|
L
 -1.8%
H
2.0
2.2
|
L
 -6.6%
H
2
2.6
|
L
 -10.5%
H
1.9
2.8
|
L
 -7.4%
H
0.4
3.9
|
L
 -98.5%
H
0.2
175
|
L
 -99.9%
H
0.2
2887.5
|
L
 -100.0%
H
0.2
131950
|
| Kura Oncology Inc |
|
849.6
|
9.6
|
L
 3.1%
H
9.3
9.6
|
L
 6.2%
H
8.8
9.6
|
L
 -21.0%
H
8.8
12.2
|
L
 1.6%
H
8.4
12.2
|
L
 72.7%
H
5.5
12.5
|
L
 -8.0%
H
5.4
24.2
|
L
 -46.1%
H
5.4
24.2
|
L
 136.9%
H
4.0
43
|
| Kymera Therapeutics Inc |
|
8,940.4
|
107.5
|
L
 1.0%
H
104.8
108.1
|
L
 4.0%
H
99.5
108.1
|
L
 -5.8%
H
99.5
120.6
|
L
 24.9%
H
69.5
130.1
|
L
 164.7%
H
36.7
130.1
|
L
 440.0%
H
9.6
130.1
|
L
 80.7%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
158.6
|
13.9
|
L
 12.6%
H
12.3
14.0
|
L
 10.0%
H
11.6
14.0
|
L
 11.4%
H
11.5
14.7
|
L
 -3.9%
H
10.6
15.3
|
L
 70.9%
H
4.9
17.4
|
L
 -71.7%
H
2.9
79
|
L
 -96.9%
H
2.9
614
|
L
 -96.2%
H
2.9
792.5
|
| Longeveron Inc (Class A) |
|
24.3
|
0.8
|
L
H
0.8
0.8
|
L
 10%
H
0.7
0.8
|
L
 20.3%
H
0.6
0.8
|
L
 -8.3%
H
0.6
0.9
|
L
 13.2%
H
0.5
1.2
|
L
 -97.7%
H
0.5
43.0
|
L
 -98.7%
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
65.8
|
3.6
|
L
 -9.6%
H
3.5
4.0
|
L
 -19.6%
H
3.1
4.7
|
L
 -48.1%
H
3.1
7
|
L
 -30.2%
H
3.1
8.4
|
L
 -25.5%
H
2.4
8.4
|
L
 24.1%
H
0.6
8.4
|
L
 -85.8%
H
0.6
49.5
|
L
 -85%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
73.5
|
0.7
|
L
 3.0%
H
0.7
0.7
|
L
 17.0%
H
0.6
0.7
|
L
 6.2%
H
0.6
0.8
|
L
 -42.0%
H
0.5
1.4
|
L
 115.6%
H
0.2
3.7
|
L
 -68.8%
H
0.2
5
|
L
 -95.6%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
432.2
|
4.2
|
L
 -1.0%
H
4.1
4.3
|
L
 8.9%
H
3.7
4.3
|
L
 15.2%
H
3.5
4.3
|
L
 4.8%
H
2.9
4.3
|
L
 16.2%
H
2.7
6.4
|
L
 5.3%
H
1.6
13.7
|
L
 -61.1%
H
1.5
15.3
|
L
 -89.2%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
360.5
|
14.7
|
L
 3.5%
H
13.9
15.1
|
L
 13.7%
H
12.7
15.6
|
L
 -4.5%
H
12.5
16.1
|
L
 -23.9%
H
11.5
20.7
|
L
 34.0%
H
9.3
45
|
L
 -69.4%
H
7.7
65.1
|
L
 -95.3%
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
126.9
|
1.9
|
L
 5%
H
1.8
1.9
|
L
 9.9%
H
1.7
1.9
|
L
 1.1%
H
1.7
1.9
|
L
 -11.3%
H
1.7
2.3
|
L
 -38.8%
H
1.6
4.7
|
L
 -10.4%
H
0.8
4.7
|
L
 -74.5%
H
0.8
9.6
|
L
 -96.3%
H
0.8
403.7
|
| Seres Therapeutics Inc |
|
48.9
|
4.9
|
L
 1.0%
H
4.8
5.2
|
L
 0.8%
H
4.7
5.7
|
L
 -31.8%
H
4.6
7.5
|
L
 -36.8%
H
4.6
8.3
|
L
 -65.7%
H
4.6
30.0
|
L
 13.5%
H
0.4
30.0
|
L
 -30.2%
H
0.4
30.0
|
L
 -49.7%
H
0.4
38.5
|
| Magenta Therapeutics Inc |
|
-
|
108.9
|
L
 -0.9%
H
106.9
113.4
|
L
 1.9%
H
103.1
114.1
|
L
 11.1%
H
91.0
114.6
|
L
 25.6%
H
68.9
114.6
|
L
 480.6%
H
18.1
114.6
|
L
 750.9%
H
10.9
114.6
|
L
 1.2%
H
5.1
135.8
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,210.4
|
13.1
|
L
 2.2%
H
12.7
13.1
|
L
 10.9%
H
11.3
13.1
|
L
 -7.6%
H
11.3
14.5
|
L
 33.1%
H
8.9
15.4
|
L
 65.9%
H
6.6
15.4
|
L
 117.8%
H
3.5
15.4
|
L
 -12.7%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,411.1
|
27.4
|
L
 1.3%
H
27.0
27.6
|
L
 7.2%
H
24.9
27.6
|
L
 -10.0%
H
24.9
30.9
|
L
 -7.4%
H
22.3
32.1
|
L
 110.4%
H
12.6
47.7
|
L
 104.6%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
798.6
|
119.2
|
L
 -0.8%
H
118.0
124.4
|
L
 10.0%
H
104.8
124.8
|
L
 20.1%
H
97.7
124.8
|
L
 87.5%
H
54.2
124.8
|
L
 244.0%
H
29.2
124.8
|
L
 2640.5%
H
1.4
124.8
|
L
 364.8%
H
1.4
124.8
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
18.7
|
1.1
|
L
H
1.1
1.1
|
L
 -0.9%
H
1.1
1.3
|
L
 -30.4%
H
1.1
1.6
|
L
 -23.3%
H
1.1
1.7
|
L
 -5.9%
H
0.8
2.5
|
L
 -75.8%
H
0.8
7.0
|
L
 -94.6%
H
0.7
21.2
|
L
 -98.3%
H
0.7
135.5
|
| Moderna |
|
23,622.8
|
59.2
|
L
 9.9%
H
54.6
59.4
|
L
 7.9%
H
52.7
59.5
|
L
 -19.8%
H
52.7
76.8
|
L
 8.9%
H
43.9
85.6
|
L
 126.5%
H
22.3
85.6
|
L
 -40.7%
H
22.3
170.5
|
L
 -85.7%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
919.0
|
6.2
|
L
 -0.3%
H
5.4
6.3
|
L
 -5.2%
H
5.4
6.7
|
L
 8.2%
H
5.4
7.4
|
L
 28.5%
H
4
7.4
|
L
 183.2%
H
2.0
7.4
|
L
 -43.9%
H
1.7
11.6
|
L
 -88.4%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
126.4
|
1.2
|
L
 6.3%
H
1.1
1.2
|
L
 12.4%
H
1.1
1.2
|
L
 -7.8%
H
1.0
1.5
|
L
 40.5%
H
0.8
1.5
|
L
 -14.5%
H
0.6
1.9
|
L
 -73.7%
H
0.6
5.5
|
L
 -92.6%
H
0.6
17.3
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
32.8
|
1.4
|
L
 4.4%
H
1.4
1.5
|
L
 26.3%
H
1.2
1.6
|
L
 6.7%
H
1.0
1.6
|
L
 300%
H
0.3
4.9
|
L
 0.7%
H
0.3
4.9
|
L
 -99.0%
H
0.3
175.2
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
2,067.4
|
15.9
|
L
 2.1%
H
15.7
16.0
|
L
 12.5%
H
14
16.0
|
L
 7.7%
H
14
19.4
|
L
 8.1%
H
13.1
19.4
|
L
 6.1%
H
12.7
21.5
|
L
 1063.5%
H
1.0
22
|
L
 117.8%
H
1.0
22
|
L
 276.8%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
151.9
|
4.1
|
L
H
4.0
4.1
|
L
 3.1%
H
4.0
4.3
|
L
 -1.0%
H
3.7
4.3
|
L
 -1.2%
H
3.7
4.4
|
L
 10.7%
H
3.5
5.4
|
L
 -33.2%
H
3.3
12.7
|
L
 -79.2%
H
3.3
32.0
|
L
 -83.4%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
47.9
|
0.3
|
L
 -3.2%
H
0.3
0.3
|
L
 -11.8%
H
0.3
0.4
|
L
 -6.3%
H
0.3
0.4
|
L
 20%
H
0.2
0.4
|
L
 -80.4%
H
0.2
2.4
|
L
 -75.8%
H
0.2
5.0
|
L
 -88.9%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
114.5
|
0.9
|
L
 1.1%
H
0.8
0.9
|
L
 -8.2%
H
0.8
1.1
|
L
 -49.4%
H
0.8
2.1
|
L
 -66.4%
H
0.8
3.2
|
L
 23.3%
H
0.6
4.3
|
L
 -71.1%
H
0.6
4.3
|
L
 -88.0%
H
0.6
8.6
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
16,610.5
|
163.4
|
L
 2.3%
H
159.7
164.8
|
L
 -2.0%
H
158.5
170.9
|
L
 -8.3%
H
158.5
186.1
|
L
 7.3%
H
150.3
186.1
|
L
 30.7%
H
122.1
186.1
|
L
 61.5%
H
84.2
186.1
|
L
 82.4%
H
71.9
186.1
|
L
 236.2%
H
37.3
186.1
|
| Nkarta Inc |
|
172.4
|
2.4
|
L
 5.2%
H
2.3
2.4
|
L
 15.3%
H
2.1
2.4
|
L
 -34.3%
H
2.0
3.7
|
L
 -24.5%
H
2.0
3.7
|
L
 21.7%
H
1.7
3.7
|
L
 14.2%
H
1.3
16.2
|
L
 -93.7%
H
1.3
40.6
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
35.7
|
L
 0.3%
H
34.6
36.7
|
L
 8.5%
H
31.9
36.7
|
L
 -6.7%
H
31.8
43.7
|
L
 16.0%
H
24.9
43.7
|
L
 68.2%
H
15.9
43.7
|
L
 178.4%
H
12.2
43.7
|
L
 -74.6%
H
7.5
169.6
|
L
 -80.5%
H
7.5
399.4
|
| MetaVia Inc |
|
7.7
|
1.5
|
L
 2.8%
H
1.4
1.5
|
L
 4.9%
H
1.4
1.6
|
L
 -4.5%
H
1.4
2.6
|
L
 36.7%
H
1.0
4.3
|
L
 -78.5%
H
1.0
19.0
|
L
 -96.8%
H
1.0
74.3
|
L
 -100.0%
H
1.0
13068
|
L
 -100.0%
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,649.5
|
25.5
|
L
 1.2%
H
25
25.9
|
L
 10%
H
22.6
25.9
|
L
 5.0%
H
21.2
25.9
|
L
 54.5%
H
14.2
25.9
|
L
 159.5%
H
8.2
25.9
|
L
 189.8%
H
4.2
29.6
|
L
 -15.9%
H
4.2
37.4
|
L
H
4.2
52.4
|
| Intellia Therapeutics Inc |
|
1,668.3
|
11.9
|
L
 6.2%
H
11.5
12.1
|
L
 11.8%
H
10.4
12.1
|
L
 -29.1%
H
10.2
17.2
|
L
 -15.3%
H
10.2
18.5
|
L
 10.7%
H
8.0
28.3
|
L
 -70.2%
H
5.9
41.0
|
L
 -92.9%
H
5.9
180.6
|
L
 -38.4%
H
5.9
202.7
|
| Natera Inc |
|
46,428.8
|
322.1
|
L
 21.4%
H
306.4
323.0
|
L
 20.3%
H
259.8
323.0
|
L
 17.4%
H
248.0
323.0
|
L
 65.8%
H
184.8
323.0
|
L
 112.0%
H
149.4
323.0
|
L
 511.0%
H
36.9
323.0
|
L
 174.6%
H
26.1
323.0
|
L
 2715.6%
H
7.4
323.0
|
| Novavax Inc |
|
1,311.3
|
8.0
|
L
 2.7%
H
7.6
8.1
|
L
 8.6%
H
7.3
8.1
|
L
 -15.0%
H
7.2
9.7
|
L
 -21.4%
H
7.2
11.6
|
L
 -5.0%
H
6.2
12.0
|
L
 10.0%
H
3.5
23.9
|
L
 -95.8%
H
3.5
277.8
|
L
 -94.7%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
6.1
|
1.5
|
L
 8.1%
H
1.3
1.7
|
L
 11.4%
H
1.3
1.7
|
L
 11.4%
H
1.2
1.7
|
L
 -30.3%
H
1.2
2.4
|
L
 -77.2%
H
1.2
7.2
|
L
 -100.0%
H
1.2
810296.8
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Insight Molecular Diagnostics Inc |
|
156.0
|
4.8
|
L
 0.6%
H
4.7
4.9
|
L
 3.9%
H
4.6
5.3
|
L
 0.8%
H
4.3
5.3
|
L
 -3.6%
H
4.3
6.9
|
L
 87.9%
H
2.3
8.5
|
L
 34.9%
H
1.9
8.5
|
L
 -95.3%
H
1.9
109.6
|
L
 -94.1%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
78.2
|
1.5
|
L
 -3.3%
H
1.5
1.5
|
L
 -11.3%
H
1.5
1.7
|
L
 -10.2%
H
1.3
1.8
|
L
 -8.6%
H
1.3
1.9
|
L
 -54.4%
H
1.3
3.3
|
L
 13.7%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
95.5
|
0.8
|
L
H
0.8
0.8
|
L
 6.7%
H
0.8
0.8
|
L
 1.3%
H
0.7
1.1
|
L
 -10.1%
H
0.7
1.2
|
L
 -7.0%
H
0.7
1.5
|
L
 -62.4%
H
0.3
2.5
|
L
 -64.1%
H
0.3
3.4
|
L
 -73.2%
H
0.3
8.5
|
| Traws Pharma Inc |
|
8.1
|
0.5
|
L
 -1.9%
H
0.5
0.6
|
L
 17.8%
H
0.5
0.6
|
L
 -19.7%
H
0.4
0.8
|
L
 -75.7%
H
0.4
3.2
|
L
 -64.7%
H
0.4
3.3
|
L
 -97.8%
H
0.4
27.5
|
L
 -99.6%
H
0.4
169.3
|
L
 -100.0%
H
0.4
23175
|
| VivoSim Labs Inc |
|
1.6
|
0.5
|
L
 42.4%
H
0.3
0.6
|
L
 38.2%
H
0.3
0.6
|
L
 -39.7%
H
0.3
1.6
|
L
 -66.2%
H
0.3
1.6
|
L
 -73.0%
H
0.3
5.3
|
L
 -97.5%
H
0.3
24.6
|
L
 -99.5%
H
0.3
99.6
|
L
 -100.0%
H
0.3
1183.2
|
| Passage Bio Inc |
|
14.1
|
4.4
|
L
H
4.4
4.6
|
L
 -1.6%
H
4.3
4.8
|
L
 -8.7%
H
4.3
5.0
|
L
 4.5%
H
3.3
6.3
|
L
 -29.8%
H
3.3
20
|
L
 -74.2%
H
3.3
35.8
|
L
 -98.3%
H
3.3
260.6
|
L
H
3.3
764.6
|
| Vaxcyte Inc |
|
8,641.1
|
58.1
|
L
 -1.4%
H
56.7
60.1
|
L
 7.4%
H
52.8
60.1
|
L
 -1.1%
H
52.5
60.2
|
L
 9.6%
H
45.3
61.8
|
L
 94.2%
H
29.5
65
|
L
 18.8%
H
27.7
121.1
|
L
 140.8%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
197.4
|
2.9
|
L
 18.3%
H
2.4
2.9
|
L
 61.9%
H
1.8
2.9
|
L
 43.2%
H
1.7
2.9
|
L
 61.9%
H
1.3
2.9
|
L
 166.4%
H
1.0
7.8
|
L
 -44.4%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
2,588.6
|
7.2
|
L
 4.6%
H
6.9
7.3
|
L
 15.3%
H
6.1
7.3
|
L
 30.0%
H
4.8
7.3
|
L
 71.7%
H
3.5
7.3
|
L
 306.2%
H
1.7
7.3
|
L
 523.3%
H
0.7
7.3
|
L
 30.0%
H
0.7
7.3
|
L
 -73.3%
H
0.7
32.9
|
| Phio Pharma Corp |
|
12.1
|
1.0
|
L
 -1.9%
H
1.0
1.1
|
L
 2.0%
H
1.0
1.1
|
L
 -3.7%
H
0.8
1.1
|
L
 -2.8%
H
0.8
1.2
|
L
 -53.8%
H
0.8
4.2
|
L
 -95.3%
H
0.6
29.1
|
L
 -99.5%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,439.5
|
34.9
|
L
 1.3%
H
34.5
35.8
|
L
 7.0%
H
31.5
36.0
|
L
 -2.8%
H
31.5
36.6
|
L
 16.0%
H
28.3
36.6
|
L
 73.5%
H
19.6
36.6
|
L
 93.1%
H
11.5
36.6
|
L
 117.2%
H
1.8
36.6
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
65.0
|
1.1
|
L
H
1.0
1.1
|
L
 1.0%
H
1.0
1.1
|
L
 -7.9%
H
1.0
1.2
|
L
 -13.9%
H
1.0
1.3
|
L
 -36.8%
H
1.0
2.0
|
L
 -94.2%
H
1.0
19.9
|
L
 -95.4%
H
1.0
36.6
|
L
H
1.0
43.9
|
| Pluri Inc |
|
19.6
|
1.8
|
L
 0.6%
H
1.8
1.8
|
L
 17.4%
H
1.5
1.9
|
L
 -4.2%
H
1.5
2.0
|
L
 -47.7%
H
1.5
3.9
|
L
 -62.2%
H
1.5
5.7
|
L
 -70.5%
H
0.7
8.5
|
L
 -92.9%
H
0.7
26.4
|
L
 -98.5%
H
0.7
169.6
|
| ProMIS Neurosciences Inc |
|
131.9
|
14.7
|
L
 10.4%
H
13.3
14.7
|
L
 7.2%
H
13.0
14.8
|
L
 6.8%
H
11.3
17.3
|
L
 49.6%
H
9.1
17.3
|
L
 4.3%
H
6.3
27.4
|
L
 -78.0%
H
6.3
77.5
|
L
 -95.0%
H
6.3
322.8
|
L
 -91.2%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
63.5
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 7.2%
H
1.0
1.2
|
L
 -4.8%
H
1.0
1.5
|
L
 -15.6%
H
1.0
1.5
|
L
 -19.6%
H
1.0
1.9
|
L
 -82.5%
H
0.8
9.7
|
L
 -96.7%
H
0.8
36.9
|
L
H
0.8
63.2
|
| Prelude Therapeutics Inc |
|
390.3
|
4.9
|
L
 4.7%
H
4.6
4.9
|
L
 6.5%
H
4.4
4.9
|
L
 -4.3%
H
3.8
5.3
|
L
 0.8%
H
3.4
5.7
|
L
 469.8%
H
0.8
5.7
|
L
 37.3%
H
0.6
6.8
|
L
 -83.7%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
558.6
|
3.1
|
L
 4.4%
H
3.0
3.1
|
L
 5.5%
H
2.7
3.2
|
L
 -33.3%
H
2.7
4.7
|
L
 -4.1%
H
2.7
4.8
|
L
 -18.5%
H
2.7
6.9
|
L
 -75.8%
H
1.1
13.6
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
336.5
|
1.6
|
L
H
1.6
1.7
|
L
 6.5%
H
1.5
1.7
|
L
 -10.9%
H
1.5
1.9
|
L
 -11.8%
H
1.5
2.2
|
L
 -36.7%
H
1.5
3.5
|
L
 -87.1%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
449.7
|
8.8
|
L
 2.1%
H
8.0
8.9
|
L
 7.9%
H
8.0
8.9
|
L
 -11.1%
H
8
10.0
|
L
 -18.4%
H
7.7
10.9
|
L
 13.9%
H
7.4
11.8
|
L
 -85.6%
H
4.3
63.6
|
L
 -84.7%
H
4.3
79.8
|
L
 -84.5%
H
4.3
79.8
|
| Quince Therapeutics Inc |
|
29.5
|
30.2
|
L
 2.2%
H
29.3
30.8
|
L
 29.1%
H
23.5
30.8
|
L
 75.1%
H
16.2
30.8
|
L
 2259.4%
H
0.8
30.8
|
L
 83.0%
H
0.8
45.5
|
L
 147.5%
H
0.8
45.5
|
L
 -95.5%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
3,220.0
|
46.4
|
L
 2.3%
H
45.0
48.1
|
L
 6.4%
H
42.2
48.1
|
L
 6.7%
H
35.3
48.1
|
L
 67.8%
H
24
50.5
|
L
 249.6%
H
8.7
71.5
|
L
 441.0%
H
3.7
71.5
|
L
 52.1%
H
3.7
71.5
|
L
 462.7%
H
3.7
82.5
|
| Rani Therapeutics Holdings Inc |
|
88.8
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 2.6%
H
0.8
0.9
|
L
 14.5%
H
0.6
0.9
|
L
 -18.6%
H
0.6
1.1
|
L
 49.1%
H
0.4
3.9
|
L
 -81.3%
H
0.4
8.8
|
L
 -93.3%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
394.2
|
3.6
|
L
 2.0%
H
3.5
3.6
|
L
 16.1%
H
3.0
3.6
|
L
 -14.9%
H
3.0
4.3
|
L
 -0.6%
H
2.5
4.3
|
L
 26.2%
H
2.5
5.5
|
L
 -78.3%
H
2.2
32.5
|
L
 -89.6%
H
2.2
37.4
|
L
 -86.7%
H
2.2
67.5
|
| Replimune Grp Inc |
|
1,013.4
|
12.1
|
L
 -6.2%
H
11.4
13.4
|
L
 7.7%
H
10.1
13.9
|
L
 8.5%
H
4.8
13.9
|
L
 196.3%
H
3.6
13.9
|
L
 128.0%
H
1.5
13.9
|
L
 -34.1%
H
1.5
21.3
|
L
 -63.0%
H
1.5
35.9
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.5
|
1.1
|
L
 1.8%
H
1.0
1.2
|
L
 20%
H
1.0
1.2
|
L
 17.5%
H
0.9
1.2
|
L
 18.8%
H
0.9
1.2
|
L
 -88.0%
H
0.9
11.7
|
L
 -100.0%
H
0.9
5417.6
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Relay Therapeutics Inc |
|
4,332.4
|
19.8
|
L
 0.1%
H
18.7
19.8
|
L
 5.0%
H
18.1
20.3
|
L
 0.7%
H
17.7
20.8
|
L
 54.9%
H
11.6
20.8
|
L
 514.0%
H
3.2
20.8
|
L
 77.0%
H
1.8
20.8
|
L
 -39.9%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Rallybio Corp |
|
85.8
|
16.2
|
L
 -0.2%
H
16.0
16.5
|
L
 1.4%
H
15.9
16.7
|
L
 3.1%
H
15.6
17.1
|
L
 12.4%
H
13.6
17.6
|
L
 280.2%
H
3.2
17.6
|
L
 -61.7%
H
1.8
50.6
|
L
 -89.2%
H
1.8
168
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
4.2
|
4.0
|
L
 -7.3%
H
4.0
4.3
|
L
 -13.2%
H
4.0
4.7
|
L
 -49.8%
H
4.0
10.7
|
L
 -45.9%
H
3.8
10.7
|
L
 -61.9%
H
3.8
21.0
|
L
 -100.0%
H
3.8
118272
|
L
 -100.0%
H
3.8
3901941.1
|
L
H
3.8
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,726.8
|
3.2
|
L
 1.3%
H
3.2
3.3
|
L
 7.3%
H
3
3.4
|
L
 -13.4%
H
2.8
3.9
|
L
 -3.0%
H
2.8
4.1
|
L
 -39.9%
H
2.8
7.2
|
L
 -72.1%
H
2.8
15.7
|
L
 -88.7%
H
2.8
29.4
|
L
H
2.8
42.8
|
| SAB Biotherapeutics Inc |
|
354.8
|
3.9
|
L
 1.3%
H
3.9
4.0
|
L
 9.2%
H
3.5
4.0
|
L
 3.5%
H
3.4
4.0
|
L
 -5.1%
H
3.3
4.3
|
L
 77.3%
H
1.9
5.2
|
L
 420%
H
0.4
6.6
|
L
 -60.6%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
979.6
|
3.5
|
L
 3.2%
H
3.4
3.5
|
L
 12.5%
H
3.1
3.6
|
L
 -11.6%
H
3.0
4.1
|
L
 0.3%
H
2.6
4.2
|
L
 17.3%
H
2.6
6.6
|
L
 -36.2%
H
1.3
12
|
L
 -81.9%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
48.3
|
1
|
L
 4.2%
H
0.9
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -15.3%
H
0.9
1.2
|
L
 -23.1%
H
0.9
1.6
|
L
 -54.1%
H
0.9
5.0
|
L
 -94.7%
H
0.9
42.2
|
L
 -99.0%
H
0.9
126.5
|
L
 -94.5%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
120.0
|
2.2
|
L
 -0.9%
H
2.2
2.2
|
L
 -2.3%
H
2.2
2.2
|
L
 -0.5%
H
1.8
2.3
|
L
 16.0%
H
1.6
2.3
|
L
 -5.7%
H
1.6
2.4
|
L
 -53.4%
H
1.5
4.5
|
L
 -93.0%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,370.5
|
8.9
|
L
 1.0%
H
8.6
9.0
|
L
 13.5%
H
7.7
9.0
|
L
 -13.7%
H
7.3
10.5
|
L
 2.3%
H
5.8
11
|
L
 -16.0%
H
5.6
12.3
|
L
 -13.7%
H
5.6
15.6
|
L
 -13.7%
H
5.6
15.6
|
L
 -13.7%
H
5.6
15.6
|
| Solid Biosciences Inc |
|
899.6
|
8.4
|
L
 -3.7%
H
8.3
8.9
|
L
 4.1%
H
7.8
9.1
|
L
 -23.7%
H
7.7
11.2
|
L
 15.4%
H
6
11.5
|
L
 33.4%
H
3.8
11.5
|
L
 118.5%
H
1.8
15.1
|
L
 -79.9%
H
1.8
51.3
|
L
H
1.8
822.6
|
| Decoy Therapeutics Inc |
|
2.1
|
3.9
|
L
 -3.2%
H
3.9
4.2
|
L
 -4.4%
H
3.8
4.5
|
L
 -31.7%
H
3.5
6.8
|
L
 -31.3%
H
3.5
13.5
|
L
 -95.6%
H
3.5
106.2
|
L
 -99.7%
H
3.5
1422.7
|
L
 -100.0%
H
3.5
43200
|
L
 -100.0%
H
3.5
11412000
|
| Summit Therapeutics Inc |
|
11,136.6
|
14.0
|
L
 3.1%
H
13.5
14.0
|
L
 7.2%
H
12.8
14.0
|
L
 -11.0%
H
12.3
15.9
|
L
 -22.8%
H
12.3
19.4
|
L
 -51.3%
H
12.3
29.4
|
L
 697.7%
H
1.5
36.9
|
L
 76.5%
H
0.7
36.9
|
L
 104.4%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,821.7
|
20.4
|
L
 3.2%
H
19.7
20.4
|
L
 7.1%
H
17.2
20.4
|
L
 -16.9%
H
17.2
25.2
|
L
 -5.1%
H
16.7
25.2
|
L
 63.5%
H
12.1
25.6
|
L
 11.8%
H
8.6
25.6
|
L
 42.6%
H
8.6
29.9
|
L
 53.6%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
628.7
|
24.4
|
L
 -0.4%
H
24.1
25.4
|
L
 -10.5%
H
23.1
28.4
|
L
 -13.0%
H
23.1
37.9
|
L
 4.2%
H
10.8
37.9
|
L
 218.8%
H
7.2
37.9
|
L
 0.0%
H
5
38.8
|
L
 -82.6%
H
5
247.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
10.9
|
0.4
|
L
 -2.8%
H
0.3
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 -66.4%
H
0.3
1.1
|
L
 -64.7%
H
0.3
1.2
|
L
 -77.9%
H
0.3
2.9
|
L
 -96.0%
H
0.3
16.9
|
L
 -64.3%
H
0.3
87.7
|
L
H
0.3
87.7
|
| Spruce Biosciences Inc |
|
129.0
|
46.9
|
L
 1.0%
H
45.9
47.4
|
L
 9.4%
H
41.5
47.4
|
L
 -5.9%
H
40.3
52.8
|
L
 -17.0%
H
40.3
59.2
|
L
 433.2%
H
7.3
240
|
L
 -71.7%
H
4.3
446.3
|
L
 -92.6%
H
4.3
644.3
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
73.0
|
1.3
|
L
 -0.8%
H
1.2
1.3
|
L
 7.7%
H
1.1
1.3
|
L
 -41.9%
H
1.1
2.3
|
L
 -50.8%
H
1.1
3.1
|
L
 -42.5%
H
1.1
3.1
|
L
 -14.9%
H
0.5
3.2
|
L
 -91.1%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
6,444.9
|
52.9
|
L
 0.5%
H
50.8
53.7
|
L
 11.9%
H
45.7
53.7
|
L
 -5.6%
H
45.7
58.5
|
L
 9.4%
H
43.2
58.5
|
L
 65.6%
H
27.1
58.5
|
L
 729.5%
H
5.9
58.5
|
L
 47.0%
H
4.3
58.5
|
L
H
4.3
70
|
| Surrozen Inc |
|
301.1
|
25.6
|
L
 18.4%
H
22.3
27.3
|
L
 15.4%
H
20.7
27.3
|
L
 12.0%
H
18.1
27.3
|
L
 -11.5%
H
18.1
31.8
|
L
 168.0%
H
9.5
35
|
L
 2950%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
2,110.7
|
32.7
|
L
 2.4%
H
31.6
32.8
|
L
 13.3%
H
28.2
33.1
|
L
 0.2%
H
27.2
33.4
|
L
 -0.6%
H
27.2
34.4
|
L
 149.7%
H
12.9
40.2
|
L
 489.4%
H
3.4
40.2
|
L
 25.0%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
694.3
|
7.3
|
L
 1.5%
H
7.2
7.4
|
L
 2.8%
H
6.9
7.9
|
L
 5.7%
H
6.1
7.9
|
L
 6.1%
H
3.3
7.9
|
L
 856.6%
H
0.7
8.3
|
L
 182.9%
H
0.7
11.8
|
L
 -64.2%
H
0.7
22.6
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
3.0
|
1.1
|
L
 -2.6%
H
1.1
1.2
|
L
 -4.3%
H
1.1
1.3
|
L
 -27.7%
H
1.1
1.7
|
L
 -27.3%
H
1.1
1.9
|
L
 -79.9%
H
1.1
8.6
|
L
 -99.7%
H
1.1
475.2
|
L
H
1.1
2076
|
L
H
1.1
2076
|
| Alaunos Therapeutics Inc |
|
4.9
|
2.0
|
L
H
2.0
2
|
L
 5.9%
H
1.9
2.0
|
L
 -3.9%
H
1.8
2.2
|
L
 -22.9%
H
1.8
3.1
|
L
 -19.4%
H
1.7
4.6
|
L
 373.8%
H
0.0
6.2
|
L
 -12.3%
H
0.0
6.2
|
L
 -59.1%
H
0.0
7.9
|
| Tscan Therapeutics Inc |
|
52.3
|
0.8
|
L
 5.3%
H
0.8
0.8
|
L
 8.1%
H
0.7
0.8
|
L
 -36.5%
H
0.7
1.3
|
L
 -36.5%
H
0.7
1.3
|
L
 -51.2%
H
0.7
2.6
|
L
 -62.8%
H
0.7
9.7
|
L
 -92.4%
H
0.7
14.7
|
L
H
0.7
14.7
|
| Bio-Techne |
|
11,263.6
|
72.3
|
L
 0.5%
H
72.0
72.3
|
L
 0.3%
H
71.9
72.3
|
L
 1.9%
H
70.8
72.4
|
L
 49.5%
H
43.2
72.4
|
L
 43.4%
H
43.2
72.4
|
L
 -14.2%
H
43.2
85.6
|
L
 -40.0%
H
43.2
136.0
|
L
 159.1%
H
23.9
136.0
|
| Instil Bio Inc |
|
50.3
|
7.4
|
L
 1.8%
H
7.3
7.5
|
L
 4.1%
H
7.0
7.5
|
L
 -4.8%
H
7.0
8
|
L
 -9.2%
H
7.0
8.3
|
L
 -73.5%
H
5.7
33.8
|
L
 1247.3%
H
0.3
92
|
L
 -56.7%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
4,407.4
|
27.1
|
L
 -6.7%
H
26.7
29.2
|
L
 -0.4%
H
25.9
30.3
|
L
 -11.7%
H
25.3
31.5
|
L
 17.6%
H
19.3
34.4
|
L
 309.5%
H
6.3
34.4
|
L
 606.8%
H
1.0
34.4
|
L
H
1.0
34.4
|
L
H
1.0
34.4
|
| Entrada Therapeutics Inc |
|
267.5
|
6.9
|
L
H
6.8
7.1
|
L
 1.2%
H
6.6
8.0
|
L
 -6.2%
H
5.7
8.0
|
L
 0.4%
H
5.6
8.1
|
L
 32.4%
H
4.9
16.5
|
L
 -55.4%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
2,637.2
|
18.5
|
L
 0.1%
H
17.9
19.3
|
L
 1.4%
H
17.5
19.3
|
L
 -0.4%
H
16.2
20.2
|
L
 27.7%
H
13.1
20.2
|
L
 149.5%
H
6.9
20.2
|
L
 704.8%
H
1.0
20.2
|
L
 807.4%
H
0.5
20.2
|
L
H
0.5
20.2
|
| Taysha Gene Therapies Inc |
|
1,885.1
|
6.6
|
L
 3.5%
H
6.4
6.6
|
L
 12.0%
H
5.6
6.6
|
L
 1.1%
H
5.3
6.6
|
L
 -3.7%
H
5.2
7.1
|
L
 141.2%
H
2.7
7.3
|
L
 811.1%
H
0.7
7.3
|
L
 -63.5%
H
0.5
21.9
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
7,253.4
|
115.7
|
L
 6.0%
H
109.3
118.3
|
L
 26.4%
H
80.6
118.3
|
L
 29.4%
H
80.6
118.3
|
L
 103.5%
H
48
118.3
|
L
 351.1%
H
23.3
118.3
|
L
 395.8%
H
14.4
118.3
|
L
 4.4%
H
11.5
140.0
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
6,605.5
|
52.0
|
L
 14.1%
H
44.4
52.2
|
L
 10.1%
H
44.4
52.2
|
L
 38.9%
H
38.3
52.2
|
L
 140.9%
H
20.2
52.2
|
L
 323.4%
H
11.2
52.2
|
L
 -4.0%
H
6.8
57.9
|
L
 -69.6%
H
6.8
191.2
|
L
H
6.8
209.0
|
| Tyra Biosciences Inc |
|
1,582.0
|
26.5
|
L
 -1.7%
H
26.1
27.8
|
L
 -16.8%
H
25.5
33.0
|
L
 -18.6%
H
25.5
33.7
|
L
 -22.8%
H
24.7
37.3
|
L
 153.7%
H
10.0
40.7
|
L
 79.6%
H
6.4
40.7
|
L
H
4.9
40.7
|
L
H
4.9
40.7
|
| Unicycive Therapeutics Inc |
|
138.9
|
5.1
|
L
 0.4%
H
5.0
5.2
|
L
 1.2%
H
4.9
5.5
|
L
 -6.6%
H
4.7
5.9
|
L
 -36.2%
H
3.9
8.7
|
L
 24.0%
H
3.7
8.7
|
L
 -42.1%
H
2.0
18.2
|
L
 -80.9%
H
2.0
33.8
|
L
H
2.0
87.3
|
| TradeUP Acq Corp |
|
-
|
0.7
|
L
 -4%
H
0.7
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 -20%
H
0.7
1.0
|
L
 -42.9%
H
0.7
1.3
|
L
 -12.2%
H
0.7
3.2
|
L
 -92.8%
H
0.7
33
|
L
H
0.7
33
|
L
H
0.7
33
|
| UroGen Pharma Ltd |
|
2,288.0
|
47.0
|
L
 3.0%
H
45.8
48.2
|
L
 22.8%
H
36.7
48.2
|
L
 23.5%
H
36.7
48.2
|
L
 59.7%
H
26
48.2
|
L
 164.7%
H
15.9
48.2
|
L
 125.3%
H
3.4
48.2
|
L
 204.3%
H
3.4
48.2
|
L
H
3.4
69.6
|
| United Therapeutics Corp |
|
23,111.2
|
538.8
|
L
 1.1%
H
524.6
541.0
|
L
 4.1%
H
490.8
541.0
|
L
 -2.8%
H
490.8
556.3
|
L
 -4.6%
H
490.8
584.7
|
L
 78.7%
H
292.3
609.4
|
L
 127.6%
H
208.6
609.4
|
L
 152.6%
H
158.4
609.4
|
L
 321.5%
H
74.3
609.4
|
| Vera Therapeutics Inc (Class A) |
|
2,360.9
|
32.9
|
L
 2.7%
H
32.1
33.1
|
L
 2.5%
H
29.5
33.1
|
L
 -22.5%
H
29.5
43.2
|
L
 -9.1%
H
29.5
44.9
|
L
 66.2%
H
19.3
56.1
|
L
 78.7%
H
9.2
56.1
|
L
 88.1%
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,492.5
|
8.8
|
L
 0.7%
H
8.8
9.0
|
L
 1.9%
H
8.5
9.7
|
L
 -15.4%
H
8.5
10.6
|
L
 -3.3%
H
8.2
10.6
|
L
 105.1%
H
4.2
11.7
|
L
 -34.0%
H
4.2
14.5
|
L
 -77.0%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
1,282.6
|
23.7
|
L
 -0.1%
H
22.7
24.3
|
L
 11.9%
H
20.2
24.3
|
L
 16.5%
H
16.7
24.3
|
L
 39.7%
H
12.6
24.3
|
L
 1043.5%
H
1.5
50.0
|
L
 800%
H
0.1
50.0
|
L
 75.3%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
610.4
|
6.7
|
L
 14.0%
H
6.0
7.1
|
L
 16.2%
H
5.6
7.1
|
L
 32.7%
H
5.0
7.1
|
L
 37.8%
H
3.4
7.1
|
L
H
3.4
11.2
|
L
 -32.8%
H
2.1
14.2
|
L
 -81.6%
H
2.1
43.0
|
L
 -57.4%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
12.9
|
0.3
|
L
 3.6%
H
0.3
0.3
|
L
 20.8%
H
0.2
0.3
|
L
 20.8%
H
0.2
0.3
|
L
 -52.5%
H
0.2
0.8
|
L
 -90.2%
H
0.2
5.1
|
L
 -96.1%
H
0.2
8.4
|
L
 -99.7%
H
0.2
97.8
|
L
 -99.7%
H
0.2
140.7
|
| Voyager Therapeutics Inc |
|
201.5
|
3.3
|
L
 4.5%
H
3.1
3.3
|
L
 7.9%
H
2.9
3.3
|
L
 -12.3%
H
2.9
3.7
|
L
 -19.3%
H
2.9
4.5
|
L
 4.1%
H
2.9
5.6
|
L
 -63.2%
H
2.6
11.7
|
L
 -1.2%
H
2.5
14.3
|
L
 -79.9%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
541.2
|
5.3
|
L
 2.3%
H
5.2
5.4
|
L
 6.6%
H
5.0
5.4
|
L
 -0.2%
H
4.8
5.4
|
L
 -5.2%
H
4.8
6.7
|
L
 -41.8%
H
4.8
12.3
|
L
 -63.3%
H
3.6
15.2
|
L
 -81.7%
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
1,202.0
|
6.1
|
L
 1.3%
H
5.9
6.2
|
L
 10.7%
H
5.4
6.2
|
L
 -2.2%
H
5.4
6.4
|
L
 -15.0%
H
5.4
7.4
|
L
 -24.6%
H
5.0
21.7
|
L
 35.6%
H
3.5
21.7
|
L
 2.7%
H
1.2
21.7
|
L
 -68.7%
H
1.2
56
|
| XBiotech Inc |
|
69.2
|
2.3
|
L
 -0.4%
H
2.3
2.3
|
L
 1.8%
H
2.2
2.3
|
L
 -3.8%
H
2.2
2.4
|
L
 -7.7%
H
2.2
2.6
|
L
 -22.3%
H
2.1
3.6
|
L
 -54.6%
H
2.1
10.0
|
L
 -86.0%
H
2.1
16.5
|
L
 -85.5%
H
2.1
26.4
|
| Exicure Inc |
|
8.5
|
1.3
|
L
 -0.7%
H
1.3
1.4
|
L
 -16.3%
H
1.3
1.6
|
L
 -21.2%
H
1.3
2.1
|
L
 -60.2%
H
1.3
3.5
|
L
 -82.0%
H
1.3
9.5
|
L
 -68.7%
H
0.3
36
|
L
 -99.3%
H
0.3
217.5
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,445.8
|
7.9
|
L
 7.7%
H
7.4
8.0
|
L
 -1.9%
H
7.1
8.4
|
L
 -8.5%
H
7.1
9
|
L
 21.4%
H
5.8
9.0
|
L
 15.9%
H
5.3
10.1
|
L
 207.4%
H
1.5
10.1
|
L
 243.3%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
460.0
|
4.6
|
L
 11.3%
H
4.2
4.8
|
L
 16.6%
H
4.0
4.8
|
L
 17.2%
H
3.6
4.8
|
L
 4.7%
H
3.6
4.8
|
L
 211.4%
H
1.4
4.8
|
L
 174.6%
H
0.2
6.6
|
L
 -23.9%
H
0.2
6.6
|
L
H
0.2
172.2
|
| Xencor Inc |
|
1,547.3
|
20.8
|
L
 4.1%
H
19.9
21.1
|
L
 3.0%
H
19.1
22.0
|
L
 26.4%
H
14.4
22.0
|
L
 61.8%
H
10.4
22.0
|
L
 187.8%
H
6.9
22.0
|
L
 -12.8%
H
6.9
27.2
|
L
 -33.3%
H
6.9
43.6
|
L
 -3.2%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.5
|
4.3
|
L
 -0.7%
H
4.1
4.5
|
L
 7.3%
H
4.0
4.5
|
L
 1.7%
H
3.6
4.7
|
L
 581.0%
H
0.3
7.3
|
L
 -88.2%
H
0.3
40.1
|
L
 -100.0%
H
0.3
2228148
|
L
 -100.0%
H
0.3
46612260
|
L
 -100.0%
H
0.3
67850460
|
| Zentalis Pharma Inc |
|
302.5
|
4.2
|
L
 -15.6%
H
4.0
4.8
|
L
 -11.0%
H
4.0
5.2
|
L
 -13.2%
H
4.0
5.6
|
L
 -4.3%
H
3.4
5.6
|
L
 193.1%
H
1.2
7.0
|
L
 -83.4%
H
1.0
29.0
|
L
 -92.0%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
566.2
|
6.0
|
L
 4.4%
H
5.7
6.0
|
L
 9.8%
H
5.3
6.0
|
L
 8.6%
H
4.9
6.0
|
L
 24.4%
H
3.3
6.0
|
L
 319.7%
H
1.4
7.4
|
L
 -9.1%
H
1.0
7.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,618.0
|
23.3
|
L
 11.7%
H
21.6
24.1
|
L
 27.6%
H
18.2
24.1
|
L
 18.1%
H
17.9
24.1
|
L
 25.4%
H
16.3
24.1
|
L
 -33.3%
H
16.0
36.8
|
L
 -3.6%
H
13.5
44.3
|
L
 -84.3%
H
13.5
155.8
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
10,197.5
|
134.8
|
L
 0.3%
H
134.5
134.9
|
L
 0.6%
H
134.0
134.9
|
L
 1.2%
H
133.3
134.9
|
L
 62.4%
H
75
134.9
|
L
 281.0%
H
34.4
134.9
|
L
 528.3%
H
14.2
134.9
|
L
H
14.2
134.9
|
L
H
14.2
134.9
|
| Intensity Therapeutics Inc |
|
11.2
|
4.2
|
L
 -2.1%
H
4.2
4.5
|
L
 0.2%
H
4
4.5
|
L
 -15.1%
H
4
5
|
L
 -18.3%
H
3.5
5.2
|
L
 -38.4%
H
3.5
43.5
|
L
 -95.9%
H
3.5
286
|
L
 -95.9%
H
3.5
286
|
L
 -95.9%
H
3.5
286
|
| Renovaro Biosciences Inc |
|
10.9
|
2.4
|
L
 -0.4%
H
2.4
2.6
|
L
 24.2%
H
1.9
3.8
|
L
 -12.0%
H
1.9
3.8
|
L
 -8.7%
H
1.8
5.0
|
L
 -87.8%
H
1.2
21.2
|
L
 -96.5%
H
1.2
420
|
L
H
1.2
420
|
L
H
1.2
420
|
| Elutia Inc (Class A) |
|
37.6
|
0.9
|
L
 -3.4%
H
0.9
0.9
|
L
 -1.2%
H
0.8
0.9
|
L
 -10.5%
H
0.8
1.0
|
L
 -15.8%
H
0.8
1.3
|
L
 -57.7%
H
0.5
2.4
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Dianthus Therapeutics Inc |
|
6,092.4
|
108.9
|
L
 -0.9%
H
106.9
113.4
|
L
 1.9%
H
103.1
114.1
|
L
 11.1%
H
91.0
114.6
|
L
 25.6%
H
68.9
114.6
|
L
 480.6%
H
18.1
114.6
|
L
 14231.6%
H
6.6
114.6
|
L
 14231.6%
H
6.6
114.6
|
L
 14231.6%
H
6.6
114.6
|
| Incannex Healthcare Ltd (ADR) |
|
37.8
|
3.2
|
L
 1.6%
H
3.1
3.2
|
L
 7.5%
H
2.9
3.2
|
L
 -6.5%
H
2.8
3.5
|
L
 -31%
H
2.8
4.7
|
L
 -76.2%
H
2.5
23.6
|
L
 -98.1%
H
2.4
160.2
|
L
 -98.1%
H
2.4
160.2
|
L
 -98.1%
H
2.4
160.2
|
| Canton Strategic Holdings Inc |
|
144.2
|
1.9
|
L
 0.5%
H
1.8
1.9
|
L
 -3.1%
H
1.8
2.0
|
L
 -19.4%
H
1.8
2.5
|
L
 -38.1%
H
1.8
3.9
|
L
 52.0%
H
1.1
9.1
|
L
 -98.5%
H
0.3
142.5
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Estrella Biopharma Inc |
|
31.0
|
0.7
|
L
 -4%
H
0.7
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 -20%
H
0.7
1.0
|
L
 -42.9%
H
0.7
1.3
|
L
 -12.2%
H
0.7
3.2
|
L
 -94.3%
H
0.6
15.5
|
L
 -94.3%
H
0.6
15.5
|
L
 -94.3%
H
0.6
15.5
|
| Lexeo Therapeutics Inc |
|
377.7
|
4.8
|
L
 5.7%
H
4.5
4.8
|
L
 16.5%
H
4.0
4.8
|
L
 -8.9%
H
4.0
5.4
|
L
 -17.5%
H
4.0
6.4
|
L
 6.2%
H
4.0
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Cartesian Therapeutics Inc |
|
267.8
|
8.9
|
L
 1.0%
H
8.6
9.0
|
L
 13.5%
H
7.7
9.0
|
L
 -13.7%
H
7.3
10.5
|
L
 2.3%
H
5.8
11
|
L
 -16.0%
H
5.6
12.3
|
L
 -99.1%
H
5.6
1278
|
L
 -99.7%
H
5.6
4230
|
L
 -99.9%
H
5.6
25199.6
|
| Elevai Labs Inc |
|
4.2
|
0.9
|
L
 -4.2%
H
0.9
1.0
|
L
H
0.9
1.0
|
L
 -13.2%
H
0.8
1.6
|
L
 -53.5%
H
0.8
2.3
|
L
 -99.4%
H
0.8
309.1
|
L
H
0.8
499117.9
|
L
H
0.8
499117.9
|
L
H
0.8
499117.9
|
| Neurogene Inc |
|
712.0
|
35.7
|
L
 0.3%
H
34.6
36.7
|
L
 8.5%
H
31.9
36.7
|
L
 -6.7%
H
31.8
43.7
|
L
 16.0%
H
24.9
43.7
|
L
 68.2%
H
15.9
43.7
|
L
 151.7%
H
6.9
74.5
|
L
 151.7%
H
6.9
74.5
|
L
 151.7%
H
6.9
74.5
|
| Cg Oncology Inc |
|
6,656.9
|
75.1
|
L
 0.3%
H
73.5
76.2
|
L
 5.5%
H
68.1
76.5
|
L
 7.6%
H
67.1
76.5
|
L
 7.9%
H
53.2
77
|
L
 202.2%
H
23.7
77
|
L
H
14.8
77
|
L
H
14.8
77
|
L
H
14.8
77
|
| FibroBiologics Inc |
|
6.5
|
1.0
|
L
 -3.9%
H
1.0
1.1
|
L
 40%
H
0.7
1.1
|
L
 19.5%
H
0.6
1.1
|
L
 -15.5%
H
0.6
1.2
|
L
 -91.6%
H
0.6
12.8
|
L
H
0.6
1100
|
L
H
0.6
1100
|
L
H
0.6
1100
|
| Alto Neuroscience Inc |
|
1,114.4
|
28.7
|
L
 0.7%
H
27.7
29.3
|
L
 5.9%
H
25.8
29.5
|
L
 9.9%
H
24.8
29.5
|
L
 18.2%
H
17.9
29.5
|
L
 833.9%
H
3.0
29.5
|
L
H
1.6
29.5
|
L
H
1.6
29.5
|
L
H
1.6
29.5
|
| Fractyl Health Inc |
|
111.1
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 -7.9%
H
0.7
1.0
|
L
 -7.9%
H
0.7
1.0
|
L
 -27.1%
H
0.4
2.4
|
L
H
0.4
15
|
L
H
0.4
15
|
L
H
0.4
15
|
| Kyverna Therapeutics Inc |
|
483.9
|
8.0
|
L
 2.7%
H
7.8
8.1
|
L
 9.0%
H
7.1
8.1
|
L
 -19.7%
H
7.0
10.2
|
L
 -14.9%
H
7.0
11.2
|
L
 145.7%
H
2.8
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
46.3
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 3.4%
H
1.2
1.3
|
L
 -4.7%
H
1.2
1.4
|
L
 -12.8%
H
1.1
1.4
|
L
 -35.9%
H
1.1
4.0
|
L
H
1.1
15
|
L
H
1.1
15
|
L
H
1.1
15
|
| NeOnc Tech Holdings Inc |
|
90.8
|
3.5
|
L
H
3.5
3.6
|
L
 0.3%
H
3.4
3.6
|
L
 -22.1%
H
3
4.6
|
L
 -35.8%
H
3
5.9
|
L
 -26.9%
H
3
13.0
|
L
H
3
13.0
|
L
H
3
13.0
|
L
H
3
13.0
|
| LENZ Therapeutics Inc |
|
168.1
|
5.4
|
L
 2.7%
H
5.2
5.4
|
L
 1.1%
H
4.9
5.5
|
L
 -12.6%
H
4.7
6.2
|
L
 -46.7%
H
4.7
10.6
|
L
 -84.5%
H
4.7
50.4
|
L
 -78.5%
H
4.7
50.4
|
L
 -78.5%
H
4.7
50.4
|
L
 -78.5%
H
4.7
50.4
|
| Boundless Bio Inc |
|
65.0
|
2.9
|
L
 1.8%
H
2.7
2.9
|
L
 15.6%
H
2.5
2.9
|
L
 18.0%
H
2.4
2.9
|
L
 100.7%
H
1.4
2.9
|
L
 167.6%
H
1.0
2.9
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
565.8
|
15.0
|
L
 -2.0%
H
14.6
15.5
|
L
 -2.9%
H
14.6
16.7
|
L
 -3.9%
H
13.3
16.7
|
L
 3.5%
H
11.2
16.9
|
L
 132.5%
H
6.2
16.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
442.3
|
6.8
|
L
 1.7%
H
6.6
6.9
|
L
 5.8%
H
6.3
6.9
|
L
 -2.2%
H
5.7
7.1
|
L
 -9.1%
H
5.6
7.8
|
L
 28.7%
H
5.0
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
19.2
|
2.7
|
L
 -4.9%
H
2.7
2.9
|
L
 -5.5%
H
2.7
3.1
|
L
 -36.3%
H
2.6
4.5
|
L
 -19.9%
H
2.6
6.9
|
L
 149.1%
H
1.5
6.9
|
L
 -67.1%
H
0.6
9.5
|
L
 -67.1%
H
0.6
9.5
|
L
 -67.1%
H
0.6
9.5
|
| Inhibrx Biosciences Inc |
|
1,300.7
|
88.7
|
L
 3.4%
H
80.4
89.3
|
L
 8.1%
H
80.4
89.3
|
L
 -8.7%
H
77.5
106.4
|
L
 -34.0%
H
77.5
151.0
|
L
 321.0%
H
20.6
155.3
|
L
 619.1%
H
12.2
155.3
|
L
 619.1%
H
12.2
155.3
|
L
 619.1%
H
12.2
155.3
|
| Rapport Therapeutics Inc |
|
2,182.5
|
45.5
|
L
 -1.9%
H
44.9
48
|
L
 11.0%
H
39.8
48
|
L
 8.3%
H
38.6
48
|
L
 19.6%
H
33.5
48
|
L
 212.7%
H
13.9
48
|
L
H
6.4
48
|
L
H
6.4
48
|
L
H
6.4
48
|
| Artiva Biotherapeutics Inc |
|
551.0
|
11.3
|
L
 -2.7%
H
10.8
12.0
|
L
 11.6%
H
9.9
12.1
|
L
 21.1%
H
8.8
12.1
|
L
 3.5%
H
6.6
12.1
|
L
 308.3%
H
2.2
14.5
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
3,266.2
|
67.8
|
L
 1.1%
H
65.3
70
|
L
 2.9%
H
62.7
72.6
|
L
 9.9%
H
52.5
72.6
|
L
 65.6%
H
28
72.6
|
L
 457.7%
H
9.6
72.6
|
L
H
4.8
72.6
|
L
H
4.8
72.6
|
L
H
4.8
72.6
|
| BioAge Labs Inc |
|
537.9
|
11.7
|
L
 4.0%
H
11.2
11.9
|
L
 29.7%
H
9.2
11.9
|
L
 -50.4%
H
8.7
25.4
|
L
 -34.9%
H
8.7
26.0
|
L
 170.7%
H
4.3
26.0
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| Voyager Acq Corp (Class A) |
|
62.9
|
2.0
|
L
 7.0%
H
1.8
2
|
L
 13.1%
H
1.8
2
|
L
 -27.9%
H
1.8
2.9
|
L
 -84.2%
H
1.7
27.4
|
L
 -80.9%
H
1.7
27.4
|
L
H
1.7
27.4
|
L
H
1.7
27.4
|
L
H
1.7
27.4
|
| OnKure Therapeutics Inc (Class A) |
|
167.7
|
4.1
|
L
 -0.2%
H
4.0
4.3
|
L
 8.4%
H
3.8
4.5
|
L
 -7.6%
H
3.7
4.6
|
L
 5.9%
H
2.9
4.8
|
L
 102.9%
H
1.9
5.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
4.2
|
L
 -5.8%
H
4.2
4.6
|
L
 22.9%
H
3.4
4.6
|
L
 1.2%
H
2.9
4.7
|
L
 -4.9%
H
2.9
5.3
|
L
 196.5%
H
1.3
7.8
|
L
 84.3%
H
1.3
7.8
|
L
 84.3%
H
1.3
7.8
|
L
 84.3%
H
1.3
7.8
|
| Upstream Bio Inc |
|
394.5
|
7.3
|
L
 5.5%
H
6.9
7.3
|
L
 14.9%
H
6.2
7.3
|
L
 -9.2%
H
6.1
8
|
L
 -20.2%
H
5.9
9.6
|
L
 -54.7%
H
5.9
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Septerna Inc |
|
1,750.3
|
38.8
|
L
 -1.8%
H
38.1
40.7
|
L
 12.7%
H
33.2
40.7
|
L
 6.7%
H
30.6
40.7
|
L
 62.7%
H
23.5
40.7
|
L
 232.2%
H
10.6
40.7
|
L
H
4.2
40.7
|
L
H
4.2
40.7
|
L
H
4.2
40.7
|
| Polyrizon Ltd |
|
24.2
|
11.6
|
L
 0.9%
H
11.0
12.2
|
L
 3.0%
H
9.5
12.2
|
L
 -20.7%
H
9.5
16.5
|
L
 -29.1%
H
9.5
18.0
|
L
 75.6%
H
2.9
18.2
|
L
H
2.9
7200
|
L
H
2.9
7200
|
L
H
2.9
7200
|
| Medicus Pharma Ltd |
|
17.0
|
0.3
|
L
 -3.2%
H
0.3
0.3
|
L
 7.1%
H
0.3
0.3
|
L
 -30.2%
H
0.3
0.4
|
L
 -11.8%
H
0.3
0.5
|
L
 -84.8%
H
0.3
3.1
|
L
 -95.5%
H
0.3
8.9
|
L
 -95.5%
H
0.3
8.9
|
L
 -95.5%
H
0.3
8.9
|
| Telix Pharma Ltd (ADR) |
|
3,902.7
|
11.5
|
L
 8.3%
H
11.4
11.6
|
L
 16.5%
H
9.9
11.6
|
L
 -0.3%
H
9.8
11.9
|
L
 7.9%
H
8.7
12.2
|
L
 1.6%
H
6.3
12.6
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
2,273.2
|
157.8
|
L
 1.8%
H
156.1
160.2
|
L
 13.5%
H
135.3
160.5
|
L
 8.7%
H
120.6
160.5
|
L
 30.1%
H
100
161.4
|
L
 285.8%
H
40.2
161.4
|
L
 1060.1%
H
11.2
161.4
|
L
 1060.1%
H
11.2
161.4
|
L
 1060.1%
H
11.2
161.4
|
| Zhengye biotech Holding Ltd |
|
89.6
|
1.9
|
L
 -9.6%
H
1.7
3.6
|
L
 42.1%
H
1.2
4.3
|
L
 145.5%
H
0.7
8.0
|
L
 99.0%
H
0.6
8.0
|
L
 -63.7%
H
0.6
13.1
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
| Sionna Therapeutics Inc |
|
2,307.6
|
51.0
|
L
 2.9%
H
49.3
55.0
|
L
 8.3%
H
45.6
55.0
|
L
 16%
H
41.7
55.0
|
L
 15.4%
H
32.3
55.0
|
L
 188.9%
H
17.1
55.0
|
L
H
7.3
55.0
|
L
H
7.3
55.0
|
L
H
7.3
55.0
|
| Zenas Biopharma Inc |
|
2,047.4
|
32.4
|
L
 0.8%
H
31.7
33.1
|
L
 3.2%
H
30.3
33.1
|
L
 12.8%
H
27.0
34.1
|
L
 65.1%
H
16.4
34.1
|
L
 121.7%
H
13.5
44.6
|
L
 209.7%
H
8.9
44.6
|
L
 209.7%
H
8.9
44.6
|
L
 209.7%
H
8.9
44.6
|
| Advanced Biomed Inc |
|
10.5
|
6.4
|
L
 -14.4%
H
6.4
7.4
|
L
 -20.4%
H
6.4
9.1
|
L
 26.4%
H
4.9
24.2
|
L
 2.9%
H
3.7
24.2
|
L
 -16.2%
H
3.6
24.2
|
L
H
3.6
82
|
L
H
3.6
82
|
L
H
3.6
82
|
| Caris Life Sciences Inc (Class A) |
|
6,426.2
|
22.7
|
L
 13.7%
H
20.1
22.8
|
L
 45.1%
H
15.8
22.8
|
L
 31.3%
H
15.1
22.8
|
L
 40.8%
H
14.2
22.8
|
L
 -23.6%
H
14.2
42.5
|
L
 -18.8%
H
14.2
42.5
|
L
 -18.8%
H
14.2
42.5
|
L
 -18.8%
H
14.2
42.5
|
| Propanc Biopharma Inc |
|
2.7
|
1.2
|
L
 -11.8%
H
1.2
1.3
|
L
 18.8%
H
1.0
1.6
|
L
 -33.3%
H
1.0
1.9
|
L
 -46.0%
H
1.0
6.8
|
L
 -98.3%
H
1.0
234
|
L
 -98.3%
H
1.0
234
|
L
 -98.3%
H
1.0
234
|
L
 -98.3%
H
1.0
234
|
| SpyGlass Pharma Inc |
|
846.2
|
25.3
|
L
 2.3%
H
23.3
26.0
|
L
 12.3%
H
21.9
26.0
|
L
 23.7%
H
19.0
26.0
|
L
 8.1%
H
17.1
26.0
|
L
 -4.1%
H
17.1
30.6
|
L
 -4.1%
H
17.1
30.6
|
L
 -4.1%
H
17.1
30.6
|
L
 -4.1%
H
17.1
30.6
|
| AgomAb Therapeutics NV ADR |
|
714.1
|
14.5
|
L
 7.4%
H
13.2
14.5
|
L
 12.7%
H
12.4
14.9
|
L
 13.8%
H
11.2
14.9
|
L
 19.5%
H
8.8
17.8
|
L
 -1.0%
H
8.8
17.8
|
L
 -1.0%
H
8.8
17.8
|
L
 -1.0%
H
8.8
17.8
|
L
 -1.0%
H
8.8
17.8
|
| Generate Biomedicines Inc |
|
1,841.9
|
14.4
|
L
 3.3%
H
14.0
14.7
|
L
 2.5%
H
13.0
15.2
|
L
 -9.6%
H
12.5
16.2
|
L
 5.1%
H
11.9
18.2
|
L
 13.4%
H
11
18.2
|
L
 13.4%
H
11
18.2
|
L
 13.4%
H
11
18.2
|
L
 13.4%
H
11
18.2
|
| Atrium Therapeutics Inc |
|
211.1
|
12.3
|
L
 1.9%
H
12.1
12.5
|
L
 8.7%
H
11.3
12.5
|
L
 -7.7%
H
11.1
13.4
|
L
 -5.6%
H
11.1
14.1
|
L
 -16.3%
H
11.1
16.8
|
L
 -16.3%
H
11.1
16.8
|
L
 -16.3%
H
11.1
16.8
|
L
 -16.3%
H
11.1
16.8
|
| Jatt II Acquisition Corp |
|
-
|
13.1
|
L
 8.5%
H
12.5
13.8
|
L
 8.5%
H
12.5
13.8
|
L
 9%
H
10.5
13.8
|
L
 24.3%
H
10
13.8
|
L
 24.6%
H
10
13.8
|
L
 24.6%
H
10
13.8
|
L
 24.6%
H
10
13.8
|
L
 24.6%
H
10
13.8
|
| Kailera Therapeutics Inc |
|
2,417.7
|
18.7
|
L
 -1.1%
H
18.4
19.3
|
L
 10.2%
H
16.7
19.3
|
L
 -14.3%
H
16.4
22.1
|
L
 -13.1%
H
16.4
24.2
|
L
 -28.2%
H
16.4
28.2
|
L
 -28.2%
H
16.4
28.2
|
L
 -28.2%
H
16.4
28.2
|
L
 -28.2%
H
16.4
28.2
|
| Alamar Biosciences Inc |
|
1,972.6
|
28.5
|
L
 1.3%
H
27.9
29.0
|
L
 12.2%
H
24.9
29.3
|
L
 12.5%
H
23.3
29.4
|
L
 18.8%
H
18.8
29.4
|
L
 29.4%
H
18.8
29.4
|
L
 29.4%
H
18.8
29.4
|
L
 29.4%
H
18.8
29.4
|
L
 29.4%
H
18.8
29.4
|
| LakewoodAmedex |
|
3.9
|
2.2
|
L
 -0.5%
H
2.1
2.3
|
L
 9.9%
H
2.0
2.5
|
L
 -6.7%
H
1.7
6.9
|
L
 -92.8%
H
1.7
33.2
|
L
 -97.4%
H
1.7
94
|
L
 -97.4%
H
1.7
94
|
L
 -97.4%
H
1.7
94
|
L
 -97.4%
H
1.7
94
|
| Hemab Therapeutics Holdings |
|
2,319.4
|
49.7
|
L
 -4.8%
H
48.6
53.3
|
L
 4.4%
H
44.7
53.6
|
L
 46.5%
H
33.6
53.6
|
L
 97.7%
H
23
53.6
|
L
 46.1%
H
23
53.6
|
L
 46.1%
H
23
53.6
|
L
 46.1%
H
23
53.6
|
L
 46.1%
H
23
53.6
|
| Odyssey Therapeutics Inc |
|
1,016.8
|
21.2
|
L
 -1.8%
H
20.9
22.3
|
L
 11.8%
H
18.0
22.3
|
L
 36.1%
H
15.5
22.3
|
L
 28.9%
H
15.1
22.3
|
L
 28.9%
H
15.1
22.3
|
L
 28.9%
H
15.1
22.3
|
L
 28.9%
H
15.1
22.3
|
L
 28.9%
H
15.1
22.3
|
| Lakefront Biotherapeutics NV |
|
1,768.1
|
27
|
L
 3.3%
H
26.6
27.1
|
L
 -0.8%
H
25.7
27.1
|
L
 -12.4%
H
25.7
30.9
|
L
 -5.6%
H
25.7
30.9
|
L
 -5.6%
H
25.7
30.9
|
L
 -5.6%
H
25.7
30.9
|
L
 -5.6%
H
25.7
30.9
|
L
 -5.6%
H
25.7
30.9
|
| Conexeu Sciences Inc |
|
215.9
|
8.1
|
L
 -4.7%
H
7.9
8.9
|
L
 -2.9%
H
7.4
10.4
|
L
 -21.2%
H
7.1
13.7
|
L
 -38.3%
H
7.1
18.8
|
L
 -38.3%
H
7.1
18.8
|
L
 -38.3%
H
7.1
18.8
|
L
 -38.3%
H
7.1
18.8
|
L
 -38.3%
H
7.1
18.8
|
| Veraxa Biotech AG |
|
281.4
|
2.0
|
L
 7.0%
H
1.8
2
|
L
 13.1%
H
1.8
2
|
L
 -27.9%
H
1.8
2.9
|
L
 -92.0%
H
1.7
26.0
|
L
 -92.0%
H
1.7
26.0
|
L
 -92.0%
H
1.7
26.0
|
L
 -92.0%
H
1.7
26.0
|
L
 -92.0%
H
1.7
26.0
|
| Kardigan Inc |
|
1,831.5
|
20.5
|
L
 0.7%
H
20.3
21.4
|
L
 -1.5%
H
19.6
21.4
|
L
 -7.7%
H
19.6
24.9
|
L
 -6.8%
H
19.6
27
|
L
 -6.8%
H
19.6
27
|
L
 -6.8%
H
19.6
27
|
L
 -6.8%
H
19.6
27
|
L
 -6.8%
H
19.6
27
|
| Braveheart Bio Inc |
|
1,284.7
|
30
|
L
 0.7%
H
28.5
32
|
L
 0.7%
H
28.5
32
|
L
 0.7%
H
28.5
32
|
L
 0.7%
H
28.5
32
|
L
 0.7%
H
28.5
32
|
L
 0.7%
H
28.5
32
|
L
 0.7%
H
28.5
32
|
L
 0.7%
H
28.5
32
|